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Abstract 
Genetic interactions have been reported to underlie phenotypes in a variety of 
systems, but the extent to which they contribute to complex disease in humans remains 
unclear. In principle, genome-wide association studies (GWAS) provide a platform for 
detecting genetic interactions, but existing methods for identifying them from GWAS 
data tend to focus on testing individual locus pairs, which undermines statistical power. 
Importantly, the global genetic networks mapped for a model eukaryotic organism 
revealed that genetic interactions often connect genes between compensatory functional 
modules in a highly coherent manner. Taking advantage of this expected structure, we 
developed a computational approach called BridGE that identifies pathways connected by 
genetic interactions from GWAS data. We examined BridGE approach with seven 
different diseases, and were able to discover significant interactions in six of them 
including Parkinson’s disease, schizophrenia, hypertension, prostate cancer, breast 
cancer, and type 2 diabetes. Our novel approach provides a general framework for 
mapping complex genetic networks underlying human disease from genome-wide 
genotype data. 
An application of BridGE with a focus on breast cancer was also extensively 
explored.  We applied the BridGE method to six independent breast cancer cohorts and 
identified significant pathway-level interactions in five cohorts. Joint analysis across all 
five cohorts revealed a high confidence consensus set of genetic interactions with support 
in multiple cohorts. The discovered interactions implicated the glutathione conjugation, 
vitamin D receptor, purine metabolism, mitotic prometaphase, and steroid hormone 
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biosynthesis pathways as major modifiers of breast cancer risk. Notably, while many of 
the pathways identified by BridGE show clear relevance to breast cancer, variants in 
these pathways had not been previously discovered by traditional single variant 
association tests or single pathway enrichment analyses that do not consider SNP-SNP 
interactions. 
Finally, we describe an application of the BridGE framework to test a specific 
hypothesis derived from studies of genetic interactions in yeast, which found that the 
proteasome complex was a genetic interaction hub. Given that proteasome function is 
highly conserved between yeast and humans, we predicted that natural variation in the 
homologous human proteasome genes would be involved in a number of disease-
modifying genetic interactions. Using BridGE, we evaluated genetic interactions across 
seven different diseases, and indeed found that the proteasome pathway was the top 
positive interaction hub among ~800 pathways examined.  
Overall, this thesis demonstrates the potential for novel computational approaches 
to translate systems-level insights across species to better elucidate the genetic basis of 
human disease. 
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Chapter 1: Introduction 
 
Several common diseases are caused by the interplay of genetic and environmental 
factors.  The discovery of the genetic factors that contribute to the development of these 
diseases can be invaluable to our society. It can provide guidance to disease diagnosis, 
stimulate the development of new and more effective drugs, and inform genetic-centric 
strategies for disease prevention.  
Our knowledge and understanding of the genetics that underlie complex diseases has 
advanced substantially in recent years. For example, mutations of LRRK2, PARK7, 
PINK1, PRKN, and SNCA were identified to be associated with impairment of neurons 
and cause Parkinson’s disease (1, 2). Gene BRCA1 and BRCA2 were found to be tumor 
suppressors and germline mutations of these two genes increase risk for breast cancer (3-
5). Another tumor suppressor gene, P53, has been frequently observed to be mutated in 
various cancers (6). Due to the availability of reliable high-throughput genotyping 
technology, in the last decade or so, there has been a dramatic increase in the study of 
genotype–phenotype association. Currently, there are more than 20,000 genetic loci-trait 
associations that have been discovered from ~2500 studies of various complex traits and 
diseases (7). For a limited number of diseases, new genetic screening tests have been 
developed based on these discoveries and used to predict disease risk or design 
personalized prevention or treatment plans. 
 However, due to the complexity of most human diseases, the precise genetic causes 
of the large majority of diseases are still unclear. Moreover, in most cases, the discovered 
single genetic variants only explain a small fraction of the estimated total heritable 
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disease risk derived from familial aggregation studies (8-13). For instance, the estimation 
of heritability in Parkinson’s disease by different studies ranged between 20% and 40% 
(14, 15), the loci discovered only explain less than 10% of the total heritable risk (14), 
suggesting there are still genetic factors that are not well-understood. 
1.1 Motivation for the Research 
The aforementioned discrepancy between the disease risk explained by known 
genetic loci and the estimated genetic heritability of a disease has been called the 
“missing heritability” problem. The “missing heritability” problem was first described 
nearly a decade ago, and numerous efforts have been made to find additional genetic 
variants for several different diseases. The genetic variation of a disease can be 
partitioned into two components: additive variation (e.g. linear combinations of single 
genetic variants) and non-additive variation (e.g. dominance and/or genetic interactions). 
Additive and non-additive variance together contribute to a measured termed “broad-
sense heritability”, while the additive variance alone defines “narrow-sense heritability”. 
Since the heritability in “missing heritability” problem refers to the additive genetic 
variance, the majority of previous efforts in the human genetics community focus on 
identifying low-frequency and rare genetic variants with small or even moderate 
contributions to disease risk using different approaches including meta-analysis and next 
generation sequencing analysis (16-21). On the other hand, although genetic interactions 
between loci are considered one potential contributor to the “missing heritability” 
problem (10, 11, 13, 22, 23), systematic approaches for discovering genetic interactions 
in complex human diseases are notably underdeveloped(13, 24). This is mainly because 
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the correction for multiple testing significantly reduced the statistical power in the large-
scale genetic association studies.  
Genetic interactions occur when joint mutations of two genes cause a phenotypic 
change that is different than expected given the effects of the individual mutations. 
Unlike in the human genetics community, genetic interactions in model organisms have 
been widely studied (25-27), and the analysis of rich, comprehensive datasets has 
produced fundamental insights into how genetic interactions are organized in a cell. For 
example, the systematic mapping of the yeast genetic interaction network revealed that 
genetic interactions tend to cluster either between or within functional modules (e.g. 
pathways or protein complexes) (25, 26, 28-31). We will refer to these two structures as 
the between-pathway model (BPM) and the within-pathway model (WPM). In particular, 
a between-pathway model connects two pathways that are functionally redundant or 
complementary to each other, so the loss of function in one pathway will less likely to 
cause a phenotypical change. Only when genes in both pathways are impaired or 
mutated, a severe loss of function phenotype can be observed. Under the within-pathway 
model, genes in the same pathway share common functions and are upstream, 
downstream or somehow co-required to accomplish that function. Mutations of one gene 
in the pathway might only cause a minor partial loss of the function, and the damage is 
not significant enough to result in a change of phenotype. However, mutations of 
multiple genes in the same pathway might lead to a complete loss of function. The 
between/within-pathway modules can be used not only to predict new functions for 
genes, but also to separate real interaction signal from noise efficiently (31). 
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Genetic interaction studies on the human population lack statistical power, which 
means that for most typical human genetic datasets, it is difficult to differentiate true 
genetic interactions from the noisy background. The statistical sensitivity, or power, of 
the traditional approach for identifying genetic interactions, which is to exhaustively test 
interactions between individual genetic variants, can be improved by increasing sample 
size. A recent simulation study estimated that significant genetic interactions could 
potentially be detected when one-half million subjects are available for genome-wide 
association testing (13). Given the rapid development of high-throughput screening 
technology, the cost of whole genome sequencing for an individual has dropped from 
$100,000,000 in 2001 to around $1000 in 2014 (32), and it is anticipated the price will to 
be further reduced to $100 in three to ten years from now (33). These developments will 
ease the statistical burden associated with studying genetic interactions in the future. 
However, the cohort sizes of the majority of human genotype datasets currently available 
are still far below the 500,000 samples required for sufficient power to discover genetic 
interactions.  
Given the observations from the global yeast genetic interaction study that genetic 
interactions are frequently organized in a functionally coherent manner, we expect these 
interaction patterns also exist in human genetics and we can leverage such expected 
structures to extract disease-specific genetic interactions out of noises. More specifically, 
we propose to take advantage of well-established pathway memberships from databases 
such as KEGG (34), Reactome (35), and Biocarta (36), and test the enrichment of genetic 
interactions between pathways or within pathways. With this approach, we also can 
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substantially reduce the number of hypothesis tests and make the discovery of statistical 
significant pathway-level interactions become possible. We expect this new approach 
will be applicable to the majority of existing genotyping datasets, potentially bring new 
insights into the underlying genetic base for complex human diseases, and further 
advance technology for disease diagnosis, treatment and prevention. 
1.2 Statistical Measurement of Genetic Interactions 
 Genome-wide association studies (GWAS), or whole genome association study 
(WGAS), are the major contributor of discoveries of genetic variants associated with 
complex human diseases over the past 10 years. A typical GWAS study is a case-control 
study that evaluates the genetic difference between two groups with shared ethnicity. One 
group includes subjects with a certain disease (cases) and another group includes healthy 
subjects (controls). For most GWAS studies performed to date, genetic variation at 
hundreds of thousands of positions throughout the genome is detected using microarray 
technology (37). In recent years, next-generation sequencing (NGS) technology also has 
made a breakthrough in studying genetic of complex human diseases. NGS provides 
broader coverage in that it can identify genetic variation anywhere in the genome, not just 
at the pre-determined loci known to exhibit variation, as is the case with microarray 
technology. Many NGS studies have thus focused on evaluating the contribution of rare 
variants or de novo mutations to disease. In this work, we focus largely on GWAS 
studies, but the concept and the pipeline developed in this work can be extended to NGS 
datasets as well. 
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 A locus identified using a standard genotyping microarray, usually referred to as a 
single nucleotide polymorhism (SNP), typically has two alleles, e.g., an A or a T. Based 
on the frequency of “A” and “T” observed in the population, the term “minor allele” (m) 
refers to the allele that occurs less frequently while the term “major allele” (M) refers to 
the allele that occurs more frequently in a given study population. For a given SNP, MM, 
Mm and mm are commonly used to denote the three genotypes, i.e., majority 
homozygous, heterozygous, and minority homozygous, respectively. A given allele could 
contribute to disease in different ways. For example, the effect of an allele at one locus 
could be additive, dominant or recessive. Depending on the disease model assumed, there 
are different ways to code SNPs. For example, assuming the minor allele is associated 
with disease, under an additive disease model, a SNP is coded as (mm=2, Mm=1, 
MM=0) because it is expected that the disease risk is associated the number of copies of 
the minor allele an individual inherits (Rmm > RMm > RMM). Under a dominant disease 
model, the disease risk is equal for individuals with either one copy or two copies of the 
affected allele (mm=1, Mm=1, MM=0). Under a recessive disease model, only 
individuals that inherited two copies of the minor allele will have the disease (mm=1, 
Mm=0, MM=0). Following these assumptions, various statistical measurements of 
genetic interactions have been developed (24, 38, 39), even though systematical detection 
of genetic interactions in complex human diseases is under-powered. In the rest of this 
section, we will introduce logistic regression and fast-epistasis, the two most widely used 
approaches for genetic interaction analysis, as well as several other methods that define 
genetic interactions, together with their advantages, limitations, and relationship to each 
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other. All computations of genetic interactions in this section were done by CASSI, a 
genome-wide interaction analysis software that is available at 
https://www.staff.ncl.ac.uk/richard.howey/cassi  (40, 41). 
Logistic regression 
Logistic regression is the traditional model for detecting interactions between two 
SNPs in GWAS studies (24, 42).  Given a SNP pair ( ,  ) and a binary class label C, we 
can fit one logistic regression model (the null model) that only includes main effects (  
and  ): 
       
 
   
             
and a second logistic regression model (the alternative model) that includes both main 
effects and an interaction term (   , and   ):  
       
 
   
                  
 Then a likelihood ratio test can be used to compare the goodness of fit of the two 
models. Logistic regression has been widely used in genetic interaction studies because 
the intuition behind the model is straightforward and easy to interpret.  
PLINK's fast- epistasis test 
The original implementation of the logistic regression model to detect genetic 
interaction in PLINK was slow due to the maximum likelihood estimations (43), so an 
alternative approach, the fast-epistasis test, was designed to evaluate genetic interaction 
in GWAS studies. Fast-epistasis is a Z-score based test that evaluates the difference in 
SNP-SNP association (odds ratio) between cases and controls (43). More specifically, 
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PLINK takes the genotype of two SNPs (X,Y) and constructs two 2x2 contingency 
tables, one for controls and one for cases, based on the count of the minor and major 
alleles in the population. The four counts in the contingency tables are          
                                         . Then the odds 
ratio between SNP   and   can be calculated separately in case and control groups: 
     
                      
                      
 
And the standard error can be estimated by: 
    
 
           
 
 
           
 
 
           
 
 
           
 
Finally, fast-epistasis compares the difference of two log odds ratios derived from case 
group and control group: 
   
                          
                 
 
Even though fast-epistasis analysis produces similar results to logistic regression in 
practice, it is suggested that this approach be used only as a screening tool (43). 
  Both logistic regression and fast-epistasis analysis are implemented in PLINK 
(43) and have been broadly used in practice. In addition to these two approaches, many 
other statistical measures for genetic interaction have been developed. Wu et al. proposed 
an odds ratio-based test based on haplotype frequencies between the two SNPs (44). 
Wellek and Ziegler suggested an analysis based on the Pearson product-moment 
correlation coefficient (45). All these statistics have a close relationship to the logistic 
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regression approach both in theory and practice (41). When we compared these 
measurements using a linkage disequilibrium filtered GWAS dataset (~15000 SNPs), we 
found that the top 1% of the interactions detected by logistic regression, fast-epistasis, 
Wu, and Wellek and Ziegler overlap with each other and the overlap coefficients range 
from 80% to 96%. More importantly, further studies have found that all of these 
approaches are sensitive to main effects that come from individual SNPs, in that the 
significance of the interaction between two SNPs can be elevated if any of the two SNPs 
has marginal association with the disease label(41). So a joint effects analysis, inspired 
by Wu, was developed to overcome this bias (41). Our data shows that this joint effect 
measure is significantly different from other methods we discussed, with only an average 
of 38% overlapping, because it controls for individual SNP’s main effect.  
Despite the prominent usage of logistic regression based approaches, algorithms 
based on a binary version of logistic regression (46), multifactor dimensionality reduction 
(MDR) (38), entropy or information theory (39) also have been developed to measure 
genetic interactions. Each of these approaches has its advantages and limitations. In 
practice, the selection of a genetic interaction analysis method should be directly linked 
to the research hypothesis of the corresponding study. In Chapter 2, we describe a new 
statistic (hygeSSI) to measure genetic interactions that explicitly captures the interaction 
between combinations of specific genotypes of two loci. 
1.3 Brief Summary of Existing Methods  
Although efficient and scalable computational tools have been developed for 
searching for interactions amongst genome wide SNPs (40, 47-49), detecting them with 
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statistical significance remains a major challenge. There are previous methods that have 
approached this problem, although from different perspectives than the methods proposed 
in this thesis. We briefly summarize those methods and describe the novelty of our 
approach relative to this body of existing work.  
 The three general directions taken by previous methods for genetic interaction 
analysis that are the most similar to our approach are: (1) gene set enrichment-based 
approaches applied to loci derived from univariate tests, (2) gene set enrichment-based 
approaches applied to SNP-level summary statistics from interactions, and (3) methods 
that use pathways as a prior to study SNP or gene level interactions or reduce the number 
of hypothesis tests. 
Gene set enrichment-based approaches applied to loci derived from univariate tests.   
Gene set enrichment analysis (GSEA) was originally developed for case-control 
gene expression datasets (50, 51) but has previously been adapted to summarize sets of 
loci (and their linked genes) derived from univariate tests applied to GWAS datasets (52, 
53). There are two key differences between these approaches and the method we propose. 
First, traditional approaches for GSEA start from univariate statistics of genes or SNPs, 
while our approach is built on interactions between pairs of SNPs that could have little or 
no single locus association with a disease phenotype. Second, approaches for GSEA 
target the enrichment of single gene/SNP associations in each individual pathway while 
our approach explores the enrichment of SNP-SNP interactions crossing each pair of 
pathways (between-pathway model or BPMs). 
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Gene set enrichment-based approaches applied to SNP-level summary statistics 
from interactions.  
The gene set enrichment approach has also been applied beyond loci derived from 
univariate analysis. Another class of methods first measure genetic interactions based on 
pairwise SNP analysis, the derive summary statistics at the individual SNP level based on 
specific interaction properties, and follow this with gene set enrichment analysis (GSEA) 
using pathway-associated SNP (or gene) interaction-based scores. For example, one such 
approach was recently applied to a bipolar study and a sporadic Amyotrophic Lateral 
Sclerosis study (54, 55). In this study, whole genome SNPs were first filtered based on 
their ECML scores (56) and only the top 1000 SNPs with the strongest main effects and 
gene-gene interactions were retained for studying SNP-SNP interactions. Then, a SNP-
SNP interaction network was constructed using a logistic regression model, and SNPs 
were ranked based on their network centrality in this network. Finally, candidate 
pathways were evaluated using a gene-set enrichment analysis based on pathway 
members’ rankings. A similar GO enrichment approach was applied to the sporadic 
Amyotrophic Lateral Sclerosis study (55), but SNP interaction strength was first 
estimated using a multiple dimension reduction (MDR) model and then summarized at a 
gene by enrichment analysis. GO annotation enrichment approaches were then applied to 
these gene-level scores. Again, these studies have not introduced the key concept that 
motivates our method:  genetic interactions connect coherently across pairs of distinct 
pathways. 
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Methods that use pathways as a prior to study SNP or gene level interactions or 
reduce the number of hypothesis tests.   
Another strategy implemented by other existing methods to address the multiple 
hypothesis testing challenge presented by pairwise SNP analysis is to reduce the number 
of hypothesis tests, based on a variety of different criteria (57). These methods typically 
employ a filtering step, either data driven (58-60) or knowledge driven (61, 62), before 
applying statistical analysis of interactions. Other illustrative examples of this class of 
approaches are from a recent autism spectrum disorder study where all possible SNPs 
were tested for interactions with the Ras/MAPK pathway (63), and a melanoma risk 
study where SNP-SNP interactions were studied within the five pathways that are 
significant based on the traditional individual SNP based-GSEA analysis (64). Most 
studies implementing this approach investigate interactions among a small set of genetic 
variants (genes or SNPs) that either statistically demonstrate evidence for individual 
association with the disease phenotype or are known to be relevant to the disease based 
on prior knowledge. Hence, systematic detection of genetic interactions among novel 
genes, or genes that show no marginal association will not be detected by these 
approaches. 
(Put an extra line break here or give this last paragraph a title) 
In summary, existing approaches are related to the proposed approach in the 
general sense that they leverage existing knowledge of pathways or other sets of 
functionally related sets of genes to either perform enrichment on univariate effects or 
interaction-based SNP summary statistics (e.g. interaction degree), or simply use 
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pathways as a prior to reduce the number of SNP pairs tested for interactions. To our 
knowledge, no existing methods explicitly test for higher-level interactions connecting 
within or between multiple pathways and are sufficiently powered to perform this 
systematically across comprehensive pathway databases. 
1.4 Organization of the thesis 
While the cost of genome sequencing is continues to decline, the cost of 
computational analysis of the data is increasing(65). With the rapidly growth in high-
throughput genetic screening technology, tremendous genetic data have been generated 
and are still growing every day.  Due to the high-dimensionality of genetic data, current 
genetic study of complex human diseases still remains at a very preliminary stage (e.g. 
univariate analysis is still the major paradigm). Many existing algorithms that have been 
successfully applied in other fields have not been applied in the field of genetics due to 
the scalability of these approaches or the complexity of biological system. There is an 
urgent need for the development of novel analytical and computational methods that can 
help us to understand complex biological systems and find the underlying genetic basis 
for complex human diseases.  
In Chapter 2, we describe a novel computational approach, called BridGE, that 
identifies pathway-level interactions from GWAS data. In addition to the development of 
pipeline, we also proposed many new statistical strategies to handle different technical 
challenges. These strategies includes a new hypergeometric based measurement for 
binary coded SNPs, a hybrid permutation procedure to increase statistical power, 
connected component analysis to handle redundancy of discoveries, among others. We 
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focus on an extensive application of BridGE to a Parkinson’s disease cohort and show 
that it is capable of discovering between-pathway and within-pathway interactions that 
are both statistically significant and biologically relevant. We describe our attempts to 
validate these discoveries in a second independent Parkinson’s disease cohort and 
demonstrate that indeed a significant fraction of discoveries were replicated. More 
broadly, we applied BridGE to an additional 6 different diseases, with statistically 
significant between-pathway or within-pathway interactions detected in  5 of these 
diseases, including schizophrenia, hypertension, prostate cancer, breast cancer, and type 2 
diabetes. Our analysis also showed statistical significant replication for 4 disease cohorts 
that have independent validation cohorts available (e.g. breast cancer, prostate cancer, 
schizophrenia). This suggests that our approach can serve as a general framework for 
mapping complex genetic networks underlying human disease from genome-wide 
genotype data. To our knowledge, this is the first work to enable systematic detection of 
genetic interactions underlying complex human diseases.  
In Chapter 3, we present a breast cancer-focused genetic interaction study. We 
applied BridGE to six independent breast cancer cohorts and discover significant 
pathway-level interactions in five cohorts. In addition to direct application of BridGE, we 
also designed a joint analysis to identify pathway-level interactions that might have 
moderate significance in multiple cohorts. Such pathways are likely to be missed due to 
the strict statistical significant cutoffs when evaluated in the individual cohort. This 
analysis revealed a high confidence consensus set of genetic interactions with multiple 
dataset support across all five cohorts. These pathways include the glutathione 
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conjugation, vitamin D receptor, purine metabolism, mitotic prometaphase, and steroid 
hormone biosynthesis pathways, and our analysis suggests they are major modifiers in 
breast cancer. Since hygeSSI is less sensitive to individual SNP’s main effect, genetic 
variants in our discovered pathways are less likely to be discovered by traditional single 
variant association tests. We expect the newly discovered breast cancer associated genetic 
variants could advance our understanding of breast cancer and promoting new strategies 
for predicting and treating breast cancer. 
In Chapter 4, we introduce a further extension of the BridGE analysis for 
identifying frequent genetic modifier pathways in complex human diseases motivated by 
observations from the recent global yeast genetic interaction study. Our analysis of 
proteasome-associated interactions in 9 GWAS studies provides strong evidence that the 
proteasome acts as a common modifier of many different human diseases. We also 
describe 4 significant proteasome specific pathway-pathway interactions in three 
different diseases (Parkinson’s disease, prostate cancer and type 2 diabetes), including an 
interaction between the proteasome and transcription that is conserved between yeast and 
human. Our study suggests that human genetic studies should be able to take advantage 
of the rich insights from model organisms and use them as guidance to advance our 
knowledge and understanding of complex human diseases. 
Finally, conclusion and proposals for future work are discussed in Chapter 5. 
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Chapter 2: Discovering Genetic Interactions 
Bridging Pathways in Genome-wide Association 
Studies 
 
This work has been submitted to Nature Genetics, and other contributors to this project 
include Gang Fang, Vanja Paunic, Hamed Heydari, Michael Costanzo, Xiaoye Liu, 
Xiaotong Liu, Benjamin Oately, Michael Steinbach, Brian Van Ness, Eric E. Schadt, 
Nathan D. Pankratz, Charles Boone, Vipin Kumar, and Chad L. Myers. More 
specifically, in the early stage of this project (before Sep 2012), Gang started this project, 
outlined the research structure, and drafted an initial manuscript of the project under the 
advisory of Chad and Vipin. Vanja contributed to the analysis of linkage disequilibrium, 
and Xiaoye performed initial data processing. Nathan offered help in processing the 
Parkinson’s disease dataset. Michael Steinbach helped to supervise the project and 
provided suggestions and comments.  Eric also provided suggestions on the project. After 
2012, Gang continuously provided feedback and suggestions on this project, as well as 
helped draft the manuscript. Hamed helped to optimize the parallel computing for the 
BridGE algorithm. Xiaotong evaluated the possibility of data imputation. Michael 
Costanzo and Charles gave constructive feedback on the project and helped to revise the 
manuscript. Chad supervised the project. 
2.1 Introduction 
Genome-wide association studies (GWAS) have been increasingly successful at 
identifying single-nucleotide polymorphisms (SNPs) with statistically significant 
association to a variety of diseases (66-70) and gene sets significantly enriched for SNPs 
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with moderate association (52, 53, 71-73). However, for most diseases, there remains a 
substantial disparity between the disease risk explained by the discovered loci and the 
estimated total heritable disease risk based on familial aggregation (8-13). While there 
are a number of possible explanations for this “missing heritability”, including many loci 
with small effects or rare variants (8-12, 74), genetic interactions between loci are one 
potential culprit (10, 11, 13, 22, 23). Genetic interactions generally refer to a combination 
of two or more genes whose contribution to a phenotype cannot be completely explained 
by their independent effects (13, 24, 75), For example, one example of an extreme 
genetic interaction is synthetic lethality, which is the case where two mutations, neither 
of which is lethal on its own, combines to generate a lethal double mutant phenotype. 
Genetic interactions allow relatively benign variation to combine and generate more 
extreme phenotypes, including complex human diseases (8-10, 13, 76). While several 
studies have reported interactions between genetic variants in various disease contexts 
(24, 47, 77-79), and though efficient and scalable computational tools have been 
developed for searching for interactions amongst genome wide SNPs (24, 40, 47, 48), 
discovering them systematically with statistical significance remains a major challenge. 
For example, recent work estimated through simulation studies that approximately 
500,000 subjects would be needed to detect significant genetic interactions under 
reasonable assumptions (13), which remains beyond the cohort sizes available for a 
typical GWAS study or even the large majority of meta-GWAS studies.  
Genome-wide reverse genetic screens in model organisms have produced rich 
insights into the prevalence and organization of genetic interactions (25, 27). Specifically, 
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the mapping and analysis of the yeast genetic interaction network revealed that genetic 
interactions are numerous and tend to cluster in highly organized network structures, 
connecting genes in two different but compensatory functional modules (e.g. pathways or 
 
Figure 2.1 Between pathway model of genetic interactions.  
An illustrative example demonstrating the concept of the between pathway model of genetic interactions. (A) Two 
distinct pathways, A→B→C and X→Y→Z converge to regulate the same essential function. Independent genetic 
perturbations in either pathway (indicated by blue color with an asterisk) have little or no contribution to a phenotype, 
but combined perturbations in both pathways in the same individual result in a genetic interaction, leading to a loss of 
function phenotype that can be associated with either an increase or decrease in disease risk. (B) The bipartite structure 
of genetic interactions resulting from functional compensation between the two pathways shown in (A). Genetic 
perturbations in any pair of genes across the two pathways combine to increase or decrease disease risk. Edges indicate 
observed interactions at the gene-gene or SNP-SNP level. (C) Conceptual overview of the BridGE method for detecting 
genetic interactions from GWAS data. 
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protein complexes) as opposed to appearing as isolated instances (25, 28-30). For 
example, nonessential genes belonging to the same pathway often exhibit negative 
genetic interactions with the genes of a second nonessential pathway that impinges on the 
same essential function (Fig. 2.1A). Due to their functional redundancy, the two different 
pathways can compensate for the loss of the other, and thus, only simultaneous 
perturbation of both pathways would result in an extreme loss of function phenotype, 
which could be associated with either increased or decreased disease risk. Importantly, 
the same phenotypic outcome could be achieved by several different combinations of 
genetic perturbations in both pathways (e.g. A-X, A-Z, B-X, B-Y, B-Z, as summarized in 
Fig. 2.1B).This model for the local topology of genetic networks, called the “between 
pathway model” (BPM), has been widely observed in yeast genetic interaction networks 
(25, 80). Indeed, as many as ~70% of negative genetic interactions observed in yeast 
occur in BPM structures, indicating that genetic interactions are highly organized and this 
type of local clustering is the rule rather than the exception (28). Combinations of 
mutations in genes within the same pathway or protein complex also exhibit a high 
frequency of genetic interaction, a scenario we refer to as the “within-pathway model” 
(WPM) (25, 80). Indeed, ~80% of essential protein complexes in yeast exhibit a 
significantly elevated frequency of within-pathway interactions (26). In the context of 
human disease, this scenario may arise for an individual inheriting two variants in the 
same pathway, resulting in reduced flux or function of a particular pathway and an 
increase or decrease in disease risk. 
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The prevalence of BPM and WPM structures observed in the yeast global genetic 
network has important practical implications that can be exploited to explore disease-
associated genetic interactions in humans based on GWAS data. Although tests to 
identify interactions between specific SNP or gene pairs are statistically under-powered, 
we may be able to detect genetic interactions by leveraging the fact that pairwise 
interactions between genome variants are likely to cluster into larger BPM and WPM 
network structures similar to those observed in the yeast global genetic network. Indeed, 
other studies exploited similar structural properties to derive genetic interaction networks 
from phenotypic variation in a yeast recombinant inbred population (81). We note that 
the method we propose here is also broadly similar to previous approaches that have used 
gene set enrichment or GO enrichment analysis to interpret SNP sets arising from 
univariate or interaction analyses (52, 53, 63, 64, 71-73, 82, 83) or aggregation tests for 
rare variants (12, 84-86). Other existing approaches have successfully identified 
interactions by reducing the test space for SNP-SNP pairs, through either knowledge or 
data-driven prioritization (58-61, 86). However, to our knowledge, no existing method 
has been developed to systematically identify between-pathway interaction structures 
based on human genetic data, which is the focus of this study. 
2.2 BridGE: a Novel Method for Systematic Discovery of Pathway Level 
Genetic Interactions from GWAS 
We developed a method called BridGE (Bridging Gene sets with Epistasis) to 
explicitly search for coherent sets of SNP-SNP interactions within GWAS cohorts that 
connect groups of genes corresponding to characterized pathways or functional modules. 
Specifically, although many pairs of loci do not have statistically significant interactions 
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when considered individually, they can be collectively significant if there is an 
enrichment of SNP-SNP interactions between two functionally related sets of genes (Fig. 
2.1B). Thus, we imposed prior knowledge of pathway membership and exploited 
structural and topological properties of genetic networks to gain statistical power to 
detect genetic interactions that occur between or within pathways in GWAS associated 
with diverse diseases. Our algorithm specifically focuses on identifying BPM structures, 
where two distinct pathways are bridged by several SNP-level interactions connecting 
them, as well as WPM structures, where interactions densely connect between SNPs 
linked to genes in the same functional module or pathway. 
Our approach involves five main components (86) (Fig. 2.1C): (I) Data 
processing consisting of sample quality control and adjustment for population 
substructure between the cases and controls to avoid false discoveries due to population 
stratification (87, 88). Linkage disequilibrium (LD) was also accounted for by pruning 
the full set of SNPs into a subset, as LD could otherwise result in spurious BPM 
structures. (II) SNP-SNP interaction networks were constructed based on SNP-SNP 
interactions scored under different disease model assumptions (additive, recessive, 
dominant, or combined recessive and dominant models). The additive disease model was 
implemented as previously described, and SNP-SNP interaction scores were derived 
based on likelihood ratio tests for models with and without an interaction term (24). 
Interactions based on recessive and dominant disease models were estimated using a 
hypergeometric-based metric that directly tests for disease association for individuals that 
are either homozygous (recessive and dominant models) or heterozygous (dominant only) 
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for the minor allele at two loci and compares the observed degree of association to the 
marginal effects of both loci. (III) The SNP-SNP network was thresholded by applying a 
lenient significance cutoff to generate a low-confidence, high-coverage SNP-SNP 
interaction network. This binary network is expected to contain a large number of false 
positive interactions, but it enables assessment of the significance of SNP-SNP 
interactions collectively at the pathway level. (IV) Pairs of pathways (for BPMs) or single 
pathways (for WPMs), as defined by curated functional standards (34-36), were tested for 
enrichment of SNP-SNP pair interactions connecting between them (or within the single 
pathway) with a chi-squared test, compared to both the global interaction density 
(       
 ) and the marginal interaction density of the two pathways (      
 ), as well as a 
permutation test (     ) conducted by randomly shuffling the SNP-pathway assignment. 
These tests produced three statistics to measure the significance of each candidate BPM 
or WPM. (V) Finally, a sample permutation strategy was applied to estimate false 
discovery rate, to correct for multiple hypothesis testing and assess the significance of the 
candidate BPMs or WPMs. Multiple hypothesis test correction is conducted only at the 
level of pathway or pathway pairs; the number of hypothesis tests performed for all 
possible pathways and all possible between-pathway combinations is substantially less 
than the number of tests for all possible SNP pairs (~10
5 
as compared to ~10
11
), which 
increases our power for discovering interactions relative to approaches that operate on 
individual SNP-SNP interactions. As part of BridGE, in addition to discovering BPM and 
WPM structures, we can also identify individual pathways that have significantly 
elevated marginal density of SNP-SNP interactions even where the interaction partners 
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do not necessarily have clear coherence in terms of pathways (called PATH structures) 
(86). In this case, we are not focused on pathway-pathway interactions but simply assess 
whether a particular pathway is a highly connected hub and associated with numerous 
SNP-level interactions. These five steps enabled us to extract statistically significant 
pathway-level interactions that can be associated with either increased risk of disease 
when pairs of minor alleles linked to two pathways occur more frequently in the diseased 
population or, conversely, decreased risk of disease when pairs of minor alleles annotated 
to two pathways occur more frequently in the control population.  
2.3 Discoveries and Their Reproducibility 
2.3.1 Discovery of between-pathway interactions in a Parkinson’s disease 
cohort 
We first applied BridGE to identify between pathway interactions in a genome-
wide association study of Parkinson’s disease (PD) (89), denoted as PD-NIA (Table 
S2.1). Recent work estimated a substantial heritable contribution to PD risk across a 
variety of GWAS designs (20%~40%) (14, 15), and although a relatively large number of 
variants have been individually associated with PD, the loci discovered to date explain  
only a small fraction (6%–7%) of the total heritable risk (14). The PD-NIA cohort used in 
this analysis consists of 519 patients and 519 ancestry-matched controls after balancing 
the population substructure (86). We compiled a collection of 833 curated gene sets 
(MSigDB Canonical pathways) (50) representing established pathways or functional 
modules from KEGG (34), BioCarta (36) and Reactome (35) (Table S2.2) and found that 
658 of these pathways were represented in the PD-NIA cohort after filtering based on 
gene set size (minimum: 10 genes or SNPs, maximum: 300 genes or SNPs). After using 
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both SNP-pathway membership permutations (NP=150,000) and sample permutations 
(NP=10) to establish global significance and correct for the multiple hypotheses tested 
(86), BridGE reported 173 total significant BPMs at a false discovery rate (FDR) of   
0.25 (              
    using a combined disease model (QQ plot in Fig. 2.2A, 
Table S2.3). Due to overlap among the pathways, these could be summarized by a less 
 
Figure 2.2 Significant pathway-pathway interactions discovered from the PD-NIA Parkinson’s disease cohort. 
 (A) Quantile-quantile (QQ) plot comparing observed p-values (based on SNP-pathway membership permutations) for 
all possible pathway-pathway interactions between the 685 pathways to the expected, uniform distribution (log10 scale). 
The horizontal line at 1x10-5 reflects the maximum resolution supported by 100,000 permutations. (B) Interaction 
between Golgi associated vesicle biogenesis pathway (Reactome) and Fc epsilon receptor I signaling pathway (KEGG). 
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Two sets of SNPs mapped to genes in these pathways are connected by grey lines that reflect SNP-SNP interactions 
above a lenient top-5% percentile cutoff. The two groups of horizontal bars (grouped and colored by chromosome) 
show the -log10 p-values derived from a single locus (univariate) test applied to each SNP individually (hypergeometric 
test), and the two dashed lines correspond to an uncorrected p ≤ 0.05 cutoff, indicating that very few of the SNPs show 
marginal significant association before multiple hypothesis test correction. (C) Null distribution of the SNP-SNP 
interaction density between the Golgi associated vesicle biogenesis pathway and Fc epsilon receptor I signaling 
pathway described in (A) based on 100,000 SNP permutations. The observed density for the Golgi associated vesicle 
biogenesis and Fc epsilon receptor I signaling interaction is indicated by the red arrow and was not exceeded by any of 
the random instances (pperm < 1×10
-5). (D) Distribution of p-values from individual tests for pairwise SNP-SNP 
interactions for SNP pairs supporting the pathway-pathway interaction, as measured by an additive disease model (-
log10 p-value). None of the SNP pairs are significant after multiple hypothesis correction (dashed line at the most 
significant SNP-SNP pair corresponds to FDR=0.94). 
 
redundant set of 23 BPMs involving 32 unique pathways (86) (a maximum overlap 
coefficient of 0.25, Fig. 2.3, Table S2.4). Some of the identified BPMs persisted at even 
the most stringent FDR cutoffs (FDR   0.05). For example, a high confidence BPM was 
identified between the Golgi associated vesicle biogenesis gene set and FcεRI signaling. 
More specifically, we observed 2281 SNP-SNP interactions between the vesicle 
biogenesis and FcεRI signaling gene sets (Fig. 2.2B), which is 1.5-fold higher than the 
expected number of SNP-SNP interactions (1510) based on the global density SNP-SNP 
interaction network and 1.3- and 1.2-fold higher than expected given the marginal density 
of the two pathways (5.9% and 6.5%), respectively (         
           , 
        
           ,             
  , Fig. 2.2C). In contrast to the significance 
of this BPM, none of the individual SNPs supporting this BPM were significant on their 
own after multiple hypothesis correction based on single-locus tests on this cohort (Fig. 
2.2B). Furthermore, none of the individual SNP-SNP interactions between the two 
pathways were significant when tested independently under an additive disease model 
(Fig. 2.2D, FDR ≥0.94), or recessive or dominant models (86) (Fig. S2.1). Thus, the 
variants involved in this pathway-pathway interaction observed in the Parkinson’s disease 
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PD-NIA cohort, would be missed based on traditional univariate analysis or interaction 
tests that focus on individual SNP pairs, but were highly significant when assessed 
collectively by BridGE. 
Furthermore, few of the pathways that we discovered as parts of significant BPMs 
(Fig. 2.3, Table S2.4) would be discovered using approaches based on pathway  
 
Figure 2.3 Global summary of between-pathway and within-pathway interactions discovered from a 
Parkinson’s disease cohort (PD-NIA). 
Network representation of a set of significant (FDR ≤0.25) between-pathway (BPM) and within-pathway interactions 
(WPM) that are associated with increased (red edges) or decreased (green edges) risk of PD. Each node indicates the 
name of the pathway or gene set, and each edge represents a between-pathway interaction or within-pathway 
interaction (self-loop edges). The size of the node reflects the number of interactions edges it has. 
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enrichment tests of single locus effects (52, 53). For example, only three pathways were 
enriched among the single-locus effects associated with PD (Golgi associated vesicle 
biogenesis, Clathrin-derived vesicle budding and the Rac-1 cell motility signaling 
pathway; Table S2.5) at the same FDR applied to the discovery of BPMs (FDR   0.25), 
and only one of these was represented as part of a BPM identified by our analysis (Table 
S2.4). We failed to identify any of the remaining 31 BPM-involved pathways through 
gene set enrichment analysis of single locus effects. 
Strikingly, the large majority (22 of 23) of discovered BPMs were associated with 
decreased risk for Parkinson’s disease (Fig. 2.3). This may suggest that, in the case of 
Parkinson’s disease, genetic interactions may be more frequently associated with 
protective effects, or alternatively, simply that there is more heterogeneity across the 
population in genetic interactions leading to increased risk, which would limit our ability 
to discover such interactions. Several BPM interactions were highly relevant to the 
biology of Parkinson’s disease. In particular, the FC epsilon receptor I (FcεRI) signaling 
pathway represented a hub in the pathway interaction network (Fig. 2.3). FcεRI is the 
high-affinity receptor for Immunoglobulin E and is the major controller of the allergic 
response and associated inflammation. In general, immune-related inflammation has been 
frequently associated with Parkinson’s disease and several immuno-modulating therapies 
have been pursued, but it remains unclear whether this is a causal driver of the disease or 
is rather a result of the neurodegeneration associated with disease progression (90, 91). 
There has been relatively little focus on the specific role of FcεRI in Parkinson’s, but 
recent observations support the relevance of this pathway to the disease (92). For 
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example, Bower et al. reported an association between the occurrence of allergic rhinitis 
and increased susceptibility to PD (93). Furthermore, reduction of IL-13, one of the 
cytokines activated by FcεRI and a member of the FcεRI signaling pathway, was shown 
to have a protective effect in mouse models of PD (94), and galectin-3, which is known to 
modulate the FcεRI immune response, was shown to promote microglia activation 
induced by α-synuclein, a cellular phenotype associated with PD (95, 96). These 
observations indicate that a hyperactive allergic response may predispose individuals to 
PD, and suggest that protective interactions reported by our method may result from 
variants that subtly reduce the activity of this pathway. Aberrant events in the Golgi and 
related transport processes have been known to play an important role in the pathology of 
various neurodegenerative diseases, including Parkinson’s disease (97, 98). Also, 
glycolytic and gluconeogenic metabolic intermediates have been found to be 
cytoprotective against 1-methyl 4-phenylpyridinium (MPP+) ion toxicity in Parkinson’s 
disease (99). Our BridGE approach also identified three protective interactions involving 
the IL-12 and STAT4 signaling pathway, a pro-inflammatory cytokine that plays a major 
role in regulating both the innate and adaptive immune responses (100). Specifically, 
microglial cells both produce and respond to IL-12 and IFN-gamma, and these comprise 
a positive feedback loop that can support stable activation of microglia (101, 102), a 
hallmark of Parkinson’s disease, particularly in later stages (103-107). The prevalence of 
the FcεRI and IL-12 interactions among the discovered interactions suggests a major role 
for immune signaling as a causal driver of PD. 
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In addition to significant between-pathway interactions, we also discovered 3 
significant WPMs associated with Parkinson’s disease risk: golgi-associated vesicle 
biogenesis (         
             ,         
             ,             
  , 
and         ), collagen mediated activation cascade (         
             , 
        
             ,             
  , and         ), and the HCMV and 
MAP kinase pathway (         
             ,         
            ,       
        , and         ) (Fig. 2.3, Table S2.4). In all three cases, minor allele 
combinations within the pathways were associated with decreased risk of PD. All three of 
these pathways were also implicated in high confidence protective BPM interactions with 
other pathways suggesting they play important roles in PD risk.  
2.3.2 Replication of pathway-pathway interactions in an independent 
Parkinson’s disease cohort 
To validate our findings, we determined if the BPM interactions discovered in the PD-
NIA cohort could be replicated in an independent PD cohort (PD-NGRC) (108); 1947 cases and 
1947 controls, all of European ancestry; subjects overlapping with PD-NIA cohort were 
removed). Indeed, 8 of the 173 total BPM interactions discovered in the PD-NIA cohort were 
nominally significant in the PD-NGRC based on all three significance criteria (86) 
(         
        ,         
        ,           ). To assess the significance of this 
level of replication across the entire set of discoveries, we compared the number of observed 
replicated BPMs at several different FDR cutoffs to the number expected by chance, which was 
estimated based on 10 random sample permutations of the validation cohort (86). Indeed, this 
analysis confirmed that the discovered interactions replicated more frequently than expected (Fig. 
2.4A, Table S2.6). For example, at an FDR cutoff of 0.05, the number of replicated BPMs was ~7 
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fold higher than expected (p = 0.02). BPMs identified at more stringent FDR cutoffs showed a 
stronger tendency to replicate in the independent cohort (Fig. 2.4A, Table S2.6), including the 
top-ranked BPM interaction we discovered between Golgi associated vesicle biogenesis and the 
 
Figure 2.4 Replication analysis of BPM interactions discovered from PD-NIA in an independent cohort (PD-
NGRC). 
 (A) Each BPM interaction discovered from the PD-NIA data was tested for replication in the PD-NGRC cohort. The 
collective significance of replication of the entire set of interactions discovered in PD-NIA was evaluated by measuring 
the fraction of significant BPMs discovered from PD-NIA that replicated in the PD-NGRC cohort (blue bars) at five 
different FDR cutoffs (x-axis). The random expectation for the number of replicating BPMs is plotted for comparison 
and was estimated based on 10 random sample permutations (grey bars). (B) Sample permutation-based approach to 
check whether the individual SNP-SNP interactions supporting the replicated pathway-level interactions are similar 
between PD-NIA and PD-NGRC. The significance of the overlap (blue dots) of SNP-SNP interactions in each of the 
BPMs replicated in PD-NGRC was assessed by a hypergeometric test. The random expectation for the level of overlap 
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was estimated by measuring the SNP-SNP interaction overlap in the same set of BPMs in 10 random sample 
permutations of the PD-NGRC cohort (gray dots) (          , Wilcoxon rank-sum test). (C) Scatter plot of the 
significance of SNP-SNP interaction overlap in each of the replicated BPMs (-log10 hypergeometric p-value) versus a 
direct measure of overlap (overlap coefficient). 
 
FC epsilon receptor I (FcεRI) signaling pathway. Intriguingly, another between-pathway 
interaction for the FcεRI signaling pathway, with a Glycolysis/gluconeogenesis gene set, also 
replicated (Table S2.6). 
While we confirmed replication of a significant fraction of the discovered interactions at 
the pathway level, this does not necessarily imply that the individual SNP pairs supporting these 
pathway-level effects are shared across cohorts. For the 8 BPMs that were validated in the PD-
NGRC cohort, we evaluated the significance of the overlap between the specific SNP-SNP pair 
interactions supporting each of the validated BPMs in the PD-NIA and the PD-NGRC cohorts 
and contrasted the observed overlap to comparable statistics from 10 random sample 
permutations of the PD-NGRC cohort. Several individual BPMs exhibited significant overlap in 
their supporting SNP-SNP interactions, and collectively, the set of 8 replicated BPMs were 
strongly shifted toward higher than expected SNP-SNP interaction overlap (86) (          ) 
(Fig. 2.4B, see Table S2.6 for a list of SNP-SNP pairs in common across cohorts). However, 
despite statistically significant overlap among SNP-SNP interactions identified in replicated 
BPMs, the extent of the observed overlap in terms of fraction of pairs was relatively low for most 
cases, with all of them exhibiting an overlap coefficient of less than 0.15 (86) (Fig. 2.4C). Thus, 
the same pathway-pathway interaction may be supported by different sets of SNP-SNP 
interactions in different populations, or alternatively, this may reflect that the power for reliably 
pinpointing specific locus pairs is limited. In either case, these results highlight the primary 
motivation for our method: genetic interactions, in particular those in a BPM structure, can be 
more efficiently detected from GWAS when discovered at a pathway or functional module level 
rather than at the level of individual genomic loci. 
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2.3.3 Discovery of pathway-level genetic interactions in five other diseases 
 
Figure 2.5 Between-pathway and within-pathway interactions discovered from 6 different diseases. 
Network representation of a set of significant between-pathway (BPM) or within-pathway (WPM) interactions (FDR ≤ 
0.25) that are associated with increased (orange edges) and decreased (green edges) risk of corresponding diseases. 
Discoveries from different diseases are indicated by different background colors. Only the most significant 10 
BPM/WPMs are shown for each GWAS cohort (see Table S2.4, S2.9-2.20 for complete list) 
 
 
We applied BridGE more broadly to an additional twelve GWAS cohorts 
representing seven different diseases (Parkinson’s disease, schizophrenia, breast cancer, 
hypertension, prostate cancer, pancreatic cancer and type 2 diabetes) (86, 109-114) 
(Table S2.1). Including PD-NIA, of the thirteen cohorts, analysis of eleven cohorts 
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(covering six different diseases) resulted in significant discoveries for at least one of the 
 
Figure 2.6 Summary of discoveries across all disease cohorts and power simulation. 
(A) The number of discoveries made in each of the disease cohorts evaluated, the disease model under which 
discoveries were made, and the direction of the disease association is reported. A complete list of interactions 
discovered is available as Table S2.4, S2.9-2.20. (B) The minimum sample sizes were estimated by simulation study 
for different pathway sizes under different conditions at the significance level of FDR < 0.25. 
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three types of interactions (BPM, WPM or PATH) at FDR   0.25. More specifically, 
significant BPMs were discovered for eight cohorts (covering six different diseases), 
significant WPMs for six cohorts (covering four different diseases) and significant PATH 
structures for six cohorts (covering three different diseases) at FDR   0.25 (Fig. 2.5, Fig. 
2.6A, Tables S2.7, S2.8, and S2.9-S2.20). The number of interaction discoveries per 
cohort varied substantially, from as low as two in one of the schizophrenia cohorts to as 
many as 50 interactions in one of the breast cancer cohorts. While we tested multiple 
disease models (additive, dominant, recessive, and combined dominant-recessive), the 
most significant discoveries for the majority of diseases examined were reported when 
using a dominant or combined model as measured by our SNP-SNP interaction metric 
(86). The relative frequency of interactions under a dominant vs. a recessive model may 
be largely due to our increased power to detect interactions between SNPs with dominant 
effects compared to recessive effects (86). 
We obtained appropriate replication cohorts for three additional diseases beyond 
Parkinson’s disease, including prostate cancer, breast cancer and schizophrenia, and were 
able to successfully replicate discovered genetic interactions for all three diseases (Table 
S2.21 replication summary). For example, three of eleven BPMs (FDR 0.25) discovered 
in the ProC-CGEMS prostate cancer cohort were replicated in the ProC-BPC3 cohort 
(7.5-fold enrichment, p = 0.01) while three of ten WPMs discovered from the ProC-
BPC3 cohort (FDR 0.25) could be replicated in ProC-CGEMS (3-fold enrichment, p = 
0.0001). For breast cancer, six of 108 significant BPMs (FDR  0.20) discovered from 
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the BC-MCS-JPN cohort replicated in the BC-MCS-LTN cohort (2-fold enrichment, p = 
0.07) and the sole significant PATH interaction discovered from the BC-MCS-LTN 
cohort replicated in the BC-MCS-JPN cohort. For schizophrenia, one of eight significant 
BPMs discovered from the SZ-GAIN cohort replicated (fold-enrichment > 10, p = 0.02), 
and the top significant WPM (FDR   0.1) also replicated in the SZ-CATIE cohort. 
The vast majority of the genetic interactions we discovered appear to be disease-
specific (Fig. 2.5, Table S2.7), and many of the pathways implicated in genetic 
interactions showed strong relevance to the corresponding disease. For example, we 
identified several cancer-related gene sets involved in replicated BPMs predicted to affect 
breast cancer risk, including p53 signaling, a basal cell carcinoma gene set, as well as an 
increased-risk interaction between MTA-3 related genes and T cell receptor activation 
initiated by Lck and Fyn. MTA-3 is a Mi-2/NuRD complex subunit that regulates an 
invasive growth pathway in breast cancer (115), and Lck and Fyn are members of the Src 
family of kinases whose expression have been found to be associated with breast cancer 
progression and response to treatment (116-118).  
We also identified and replicated multiple prostate cancer risk-associated 
interactions that involved DNA repair, PD-1 (Programmed cell death protein 1) signaling, 
and insulin regulation pathways. Consistent with our findings, metabolic syndrome has 
been recently associated with prostate cancer (119), and serum insulin levels have been 
shown to correlate with risk of prostate cancer (120). We also identified a replicating 
interaction associated with decreased risk of prostate cancer between the p38 MAPK 
signaling and AKAP95 chromosome dynamics pathways. P38 MAPK signaling has been 
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associated with a variety of cancers (121), and AKAP95 is an A kinase-anchoring protein 
involved in chromatin condensation and maintenance of condensed chromosomes during 
mitosis (122) whose expression has been previously implicated in the development and 
progression of rectal and ovarian cancers (123). We also discovered and replicated two 
WPMs associated with prostate cancer risk. The first involves the antigen processing and 
presentation pathway (associated with increased risk) and a second involving a gene set 
associated activation of ATR in response to replication stress (associated with decreased 
risk). Both of these pathways have strong relevance to cancer risk (124, 125). 
For schizophrenia, we discovered and replicated a BPM interaction comprising a 
gene set associated with the HIV life cycle and a vitamin and cofactor metabolism 
pathway. Interestingly, a recent large Danish schizophrenia study reported that 
schizophrenia patients are at a 2-fold increased risk of HIV infection, and conversely, that 
individuals infected with HIV exhibited increased risk of schizophrenia, especially in the 
year following diagnosis (126). Our finding suggests a common genetic basis between 
risk factors for schizophrenia and host response to the HIV virus, which may help to 
explain the observed co-morbidity of these diseases. We also discovered and replicated a 
protective WPM for schizophrenia in the nicotinate and nicotinamide metabolism 
pathway. Nicotinic acid (vitamin B3) supplements have been pursued as a treatment for 
schizophrenia dating back to the 1950s (127). Interestingly, after an initial series of 
reports of promising treatments, several follow-up studies had difficulty reproducing the 
beneficial effects of nicotinic acid (128), which could be a result of modifier effects 
within this pathway.   
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Although we did not conduct replication analyses for hypertension or type 2 
diabetes, we found that many of the pathways involved in interactions from the discovery 
cohorts were also highly relevant to the corresponding disease. For example, in the 
hypertension cohort, we identified a risk-associated BPM interaction involving hypoxia 
inducible factor (HIF) signaling, whose aberrant expression has been previously 
associated with hypertension (129). Two BPMs and one WPM, all associated with 
increased risk, involved the Rho cell motility signaling pathway, which has been 
previously implicated in the pathogenesis of hypertension (130). For type 2 diabetes, we 
discovered BPMs associated with protective effects involving an autoimmune thyroid 
disease gene set, glycosaminoglycan biosynthesis, and the mTOR signaling pathway, all 
of which have strong links to diabetes (131-133). In summary, BridGE was able to detect 
all possible types of pathway-level genetic interactions (BPM, WPM and PATH) across 
several diverse disease cohorts, highlighting the utility of our method and the potential 
for genetic interactions to underlie complex human diseases. 
We should note that while these pathways discussed are clearly relevant to the 
corresponding diseases, this discussion reflects our selection of a few individual cases. 
Full confidence in the relevance of these pathways to each disease will require in-depth 
experimental validation. More systematic evaluation of the entire set, while controlling 
for the possibility that given a large set of pathways, one can often find a small subset 
associated with the disease, would also be worthwhile. 
2.4 Simulation study to evaluate the power of BridGE approach 
Several of our results indicate that the additional power gained by aggregating 
SNPs connecting between or within pathways is critical for discovering genetic 
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interactions from GWAS, at least based on the cohort sizes analyzed here. To fully 
explore the limits of our approach, we carried out a simulation study to estimate the 
statistical power afforded by the BridGE method with respect to sample size, interaction 
effect size, minor allele frequency, and pathway size, all of which should affect the 
sensitivity of detection of pathway-level genetic interactions. 
We focused our power analysis on the detection of BPMs, which comprise most 
of our discoveries. Briefly, our simulations involved two components: one in which 
individual SNP-SNP pairs were embedded in a simulated population cohort with varying 
allele frequency (134), and another component that simulated the rate of detection of 
increasingly larger BPM interaction structures given the corresponding level of false 
positives in the SNP-level network as determined by the first component (86). Indeed, we 
found that each of the evaluated parameters (sample size, interaction effect size, minor 
allele frequency, and pathway size) affected the power of our approach (Fig. 2.6B). As 
expected, the sensitivity of our method increases with increasing pathway size, which is a 
key motivation for the approach. For example, our power analysis indicated that a 
minimum cohort size of 5000 individuals (2500 cases, 2500 controls) is required to detect 
a 25×25 BPM (i.e. two interacting pathways with 25 SNPs mapping to each pathway) 
that confers a 2X increase in risk with a minor allele frequency (MAF) of 0.05 (FDR < 
25%) while a 300x300 BPM with the same effect size would require only 1000 
individuals (500 cases, 500 controls) for detection at the same level of significance 
(simulation results for more stringent FDR cutoffs). As expected, the sensitivity of the 
approach also increases for interactions involving SNPs with higher MAF. For example, 
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the same 25x25 BPM involving variants at MAF of 0.15 conferring 2X increase in risk 
can be detected from cohorts as small as 2000 individuals (1000 cases, 1000 controls), 
and a 300x300 BPM with these characteristics could be detected from a cohort as small 
as 500 individuals (250 cases, 250 controls). A key parameter affecting these power 
estimates is the assumed biological density of interactions, which we define as the 
fraction of SNP-SNP pairs crossing two pathways of interest that actually have a 
functional impact on the disease phenotype relative to all possible SNP-SNP pairs. We 
assumed a density of 5% for the power analysis reported here (analysis based on 2.5% 
and 10% are included in Fig. S2.2), meaning that the fraction of SNP-pairs that have the 
potential to jointly influence the phenotype comprise only a small minority of all possible 
SNP pairs. In practice, we anticipate that this frequency varies substantially across 
different pathways, depending on the frequency of functionally deleterious SNPs that are 
present in the population for each pathway. A higher density of functionally deleterious 
SNPs will result in higher sensitivity of our approach and vice versa, a lower density of 
functionally deleterious SNP combinations can substantially reduce the sensitivity of our 
approach (Fig. S2.3). Notably, while statistical power increases with pathway size (i.e. 
number of SNPs mapping to each pathway), this is only true under the assumption that 
the SNPs (and the corresponding genes) actually contribute in a functionally coherent 
manner to the particular pathway or functional module. On the real disease cohorts, we 
discovered interactions for a large range of pathway sizes (Fig. S2.4), suggesting there 
are even relatively small functional modules (e.g. less than 20 associated SNPs) that have 
sufficiently strong interaction effects to be detected. In general, these power analyses 
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confirm that our approach is sufficiently powered to discover pathway-level genetic 
interactions at moderate effect size (~1.5-2X increased/decreased risk) for relatively 
small cohorts (~1000 or more individuals), which suggests it could be broadly applied to 
discover interactions in hundreds of existing GWAS cohorts that have been previously 
analyzed using only univariate approaches (135). 
2.5 Discussion 
We described a novel and systematic approach for discovering human disease-
specific, pathway-level genetic interactions from genome-wide association data. Results 
from eleven GWAS cohorts representing six different diseases confirmed that interaction 
structures prevalent in genetic networks of model organisms are indeed apparent in 
human disease populations and that these structures can be leveraged to discover 
significant genetic interactions either between or within biological pathways or functional 
modules. Genetic interactions discovered for these six diseases have the potential to 
contribute substantially to our understanding of their genetic basis. For example, to date, 
there have been approximately 85 singly associated loci (p ≤1.0×10-7) and one genetic 
interaction (between FGF20 and MAOB) reported for Parkinson’s Disease (136, 137). 
Here, we discovered 23 more pathway level genetic interactions, emphasizing the 
potential of our approach to expand our knowledge of the contribution of genetic 
variation associated with diseases such as PD. Indeed, many of the pathways discovered 
by our approach have not been previously implicated in these diseases. For example, the 
median percentage of BridGE-identified pathways for which there was at least one linked 
SNP reported in dbGaP across the six diseases was 22% (Table S2.22), indicating that the 
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large majority of our discoveries represent novel insights that could not be made using 
standard single-locus approaches. 
There are several ways the BridGE method could be expanded and improved 
upon to better detect genetic interactions. First, our approach currently depends on 
literature-curated collections of biological pathways as a major input. The potential of our 
method to detect genetic interactions within or between well-defined pathways and 
functional modules could be substantially improved as more complete curated or data-
derived functional standards are developed and integrated with the approach, which will 
be a focus of future work. Second, to avoid spurious network structures related to SNPs 
that map to genes located in close physical proximity or linkage disequilibrium (LD), we 
sampled a conservatively sized subset of tag SNPs to run our analysis for each dataset. 
This conservative approach has undoubtedly missed functional variants that may 
contribute to disease risk. More sophisticated approaches for retaining a larger set of tag 
SNPs while still controlling for LD structure could improve the sensitivity of our method. 
Finally, we emphasize that our study focuses exclusively on detecting pathway level 
genetic interactions between common variants assayed by typical GWAS. Continued 
development to examine the contribution of rare variants or interactions between rare 
variants and other loci, or to leverage the full set of variants identified through whole-
genome or exome sequencing represent logical extensions of the BridGE approach. 
Developing mechanistic or clinically actionable disease insights based on the 
genetic interactions we have discovered will require additional strategies that build on 
pathway-level discoveries to generate more targeted hypotheses, followed by functional 
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studies in disease models. One potential strategy to generate more targeted hypotheses 
involves leveraging an approach like BridGE to find pathways with robust disease-
associated genetic interactions followed by a more targeted search for individual SNP-
SNP or gene-gene pairs within these pathways that explain these structures. Our analysis 
of the Parkinson’s cohort indicated that there is indeed significant overlap among the 
strongest SNP-SNP interactions underlying replicated pathway level interactions, 
supporting the potential utility of this hierarchical approach.  
The extent to which genetic interactions contribute to the genetic basis of human 
disease has been the subject of recent debate (13, 138, 139). This debate is in part fueled 
by differences in language among geneticists that regularly encounter physiological 
epistasis between specific alleles and statistical geneticists who instead study statistical 
epistasis, which measures the non-additive component of genetic variance in a population 
(138, 140). The target of our method is to discover disease-relevant physiological 
epistasis between sets of specific alleles in biological pathways based on population 
genetic data. Robust estimates of the additional heritability explained by pathway level 
genetic interactions discovered by our method will be a focus of future work, but we 
anticipate this still remains just one of many contributions to heritability. Even in cases 
where the contribution to disease heritability is modest, genetic interactions define 
genetically distinct disease subtypes and point toward new insights about disease 
mechanism that can seed the search for new, targeted therapies. Also, recent studies 
suggest that accurately predicting the phenotypes of individuals from genotypes can 
depend critically on understanding interactions between genetic loci (138, 141), and thus, 
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progress in personalized genome interpretation and medicine depends on our 
understanding of how specific alleles interact to cause phenotypes. Our work establishes 
a new paradigm for approaching this problem and provides a systematic method for 
detecting genetic interactions that can be applied to existing population genetic data for a 
variety of human diseases. 
2.6 Methods 
2.6.1 Genome-wide association studies (GWAS) datasets 
Twelve GWAS datasets, representing 13 different cohorts covering seven 
diseases, were used in this paper: Parkinson’s disease (PD-NIA: phs000089.v3.p2, PD-
NGRC: phs000196.v1.p1), breast cancer (BC-CGEMS-EUR, BC-MCS-JPN and BC-
MCS-LTN: phs000517.v3.p1), schizophrenia (SCHZ-GAIN: phs000021.v3.p2; SCHZ-
CATIE: CATIE study), hypertension (HT-eMERGE: phs000297.v1.p1; HT-WTCCC: 
cases are from EGAD00000000006, controls are from EGAD00000000001 and 
EGAD00000000002), prostate cancer (ProC-CGEMS: phs000207.v1.p1; ProC-BPC3: 
phs000812.v1.p1), pancreatic Cancer (.PanC-PanScan: phs000206.v3.p2) and Type 2 
Diabetes (T2D-WTCCC: cases are from EGAD00000000009, controls are from 
EGAD00000000001 and EGAD00000000002). These data sets were obtained from three 
resources: dbGaP (135), Wellcome Trust Case Control Consortium or the National 
Institute of Mental Health (NIMH) (142). Details of each dataset (e.g. sample size, 
genotyping platform) are summarized in Table S2.1. 
2.6.2. Data processing 
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We used the same set of pre-processing steps for all GWAS data sets analyzed in 
this paper. Each of the steps is outlined in detail in the sections that follow. 
Sample quality control  
We first controlled data quality using the standard PLINK inclusion procedure 
with the following parameters: 0.02 as the maximal missing genotyping rate for each 
individual/SNP (--mind, --geno), 0.05 as the minimum minor allele frequency (--maf), 
and 1.0      as the Hardy-Weinberg equilibrium cutoff (--hwe 1e-6).  
To identify outlier samples that were not consistent with the reported study population, 
we mapped SNPs in each GWAS dataset to Genome Reference Consortium GRCh37 
(143) and combined the samples with the 1000 Genomes data (144) (all ancestry groups). 
We then used PLINK to perform multi-dimensional scaling (MDS) analysis. Based on 
the MDS plot, we removed samples that were not tightly clustered with the corresponding 
ancestry groups in the 1000 Genomes data. For the two Parkinson’s disease cohorts, we 
followed the previous study (145) to remove samples that are likely outliers. For these 
cohorts, duplicate subjects were kept in just one cohort with priority given to PD-NIA 
over the PD-NGRC cohort, so that we could retain as many samples as possible for the 
smaller cohort.  
Population stratification  
Checking relatedness among individuals. Relatedness among each pair of subjects was 
tested by calculating IBD (43). For subject pairs with a proportion IBD score greater than 
0.2, one was randomly chosen and removed from the data, and the other was kept.  
  45 
Matching population structure between cases and controls. Because spurious allelic 
associations can be discovered due to unknown population structure (87, 146, 147), 
recent GWAS analyses suggest the use of a procedure to ensure balanced population 
structure between cases and controls (43). Here, all subjects were clustered into groups of 
size 2, each containing one case and one control that are from the same sub-population 
(based on pairwise identity-by-state distance and the corresponding statistical test), as is 
implemented in PLINK (43).  
Future extensions of our method could include parameters capturing population 
structure directly in the model for genetic interactions, for example, as is described in 
(148) . The primary concern in developing and applying our current approach was to 
ensure that population structure was not introducing spurious between-pathway 
interactions, so we took this relatively conservative approach to adjust for population 
stratification. More sophisticated approaches could reduce the number of samples lost in 
filtering based on population stratification and improve the sensitivity of the method. 
Filtering SNPs in linkage disequilibrium (LD) 
For each data set, we selected all SNPs that could be mapped to at least one of the 
6744 genes in the collection of pathways used in the pathway-pathway interaction search. 
A SNP was mapped to all genes that overlap with a +/- 50kb window centered at the 
SNP, and then mapped to pathways to which the corresponding gene(s) were annotated. 
For the purposes of computing pathway-level statistics, a SNP was only associated once 
with each pathway, even if it mapped to multiple genes in the pathway. 
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To avoid the discovery of trivial bipartite structures, SNPs in linkage 
disequilibrium (LD) need to be removed before between or within-pathway enrichment 
of SNP-SNP interactions is conducted. Two general approaches can be pursued towards 
this goal: 1) removing SNPs in LD before calculating pairwise SNP-SNP interactions; 
and 2) removing structures that emerge as a result of SNPs in LD after calculating 
pairwise SNP-SNP interactions.  
The first alternative is more likely to miss informative SNP-SNP interactions than 
the second because it only considers a subset of all SNPs, but is more computationally 
efficient and scalable. It is worth noting that a biclustering algorithm pursuing the second 
approach was designed in (81) to condense a yeast SNP-SNP interaction network into an 
LD-LD network. The algorithm described in that work took the SNP-SNP interaction 
matrix as input and searched for sets of consecutive SNPs that had a statistically 
significant number of across-set SNP-SNP interactions based on a hypergeometric test. 
The algorithm was applied on a yeast SNP-SNP interaction network (originally 
constructed in (149)) with 1977 SNPs, where the LD effect was assumed to be localized 
to less than 60 SNPs for computational reasons
1
. We attempted to apply this algorithm to 
the human genotype datasets used in this paper and observed that the algorithm could 
handle about 1500 SNPs with a threshold of σ below 60) but not beyond. For example, on 
a data set with 2000 SNPs, the program did not finish in two days with σ = 100. Given 
issues with scalability of this approach, we adopted the first alternative, which is to select 
a subset of SNPs that are not in LD. 
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To accomplish this, we used a procedure in PLINK (43) to select a subset of 
unlinked SNPs from each GWAS dataset, specifically “-indep-pairwise 50 5 0.1”. With 
this procedure, PLINK searches each window of 50 SNPs with a sliding step of 5 SNPs, 
and selects a subset of SNPs with pairwise r
2
 below 0.1 within each sliding window. 
After this procedure, ~15,000-20,000 SNPs were left in each dataset, and the highest r
2
 
between any pair of SNPs within any window of 1Mb is lower than the commonly used 
threshold for controlling LD (r
2
 < 0.2) (53, 150), demonstrating that the LD was 
effectively controlled. Note that by using a stringent r
2
 threshold of 0.1, we are 
undoubtedly ignoring many informative SNPs. However, we chose this conservative 
approach to minimize the chance that spurious BPMs resulted from remaining LD 
structure. Future work that explores less conservative approaches to handling SNPs in LD 
would be worthwhile. 
For diseases that we tested for replication of discovered interactions on 
independent cohorts of the same ancestry, to make the discovery and replication analysis 
consistent for these instances, cohorts were first combined and then processed using the 
procedures described above to select the subset of SNPs on which the analysis was run. 
After selection of SNPs, population stratification and discovery of interactions was then 
performed independently. We followed this procedure for three of the diseases analyzed, 
Parkinson’s disease, schizophrenia, and breast cancer. For prostate cancer, our access to 
ProC-CGEMS and ProC-BPC3 was gained at different times, so SNPs used in ProC-
BPC3 were selected based on the CGEMS cohort. A summary of all processed datasets 
used in this study is included in Table S2.1. 
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Selection of Pathways 
833 human pathways (gene sets) were collected from the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (151, 152), Biocarta(153), and Reactome(35)  (Table S2.2). 
We excluded any pathway from our analysis with less than 10 or more than 300 genes, or 
less than 10 or more than 300 SNPs, mapping to the pathway after LD control to avoid 
pathways that were too small to provide sufficient statistical power or too large to provide 
specific biological insights.  
2.6.3 SNP-SNP genetic interaction estimation 
MM, Mm and mm are used to denote the three genotypes of each SNP, i.e., 
majority homozygous, heterozygous and minority homozygous, respectively. Our method 
implements multiple disease models, which affect how interactions are estimated at the 
SNP-SNP interaction level. A minor allele (m) at each locus could be additive, dominant 
or recessive in the context of different diseases. For the additive model, we used the 
standard logistic regression-based model implemented in CASSI (40) to quantify the 
interaction between two SNPs coded as follows, mm=2, Mm=1, MM=0. In this model, 
the goodness-of-fit was compared between a standard logistic regression model with an 
interaction term between the two loci of interest and a standard logistic regression 
without an interaction term, and the significance of the interaction was measured by a 
likelihood ratio test (40). We refer to this type of SNP-SNP interaction as an additive-
additive (AA) model based interaction. In the dominant model, a SNP is encoded as 
mm=1, Mm=1, MM=0. In the recessive model, a SNP is encoded as mm=1, Mm=0, 
MM=0. Because the minor allele could have recessive (R) or dominant (D) contribution 
to disease at two different loci comprising an interaction, four types of SNP-SNP 
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interactions were examined: recessive-recessive (RR), dominant-dominant (DD), 
recessive-dominant (RD), and dominant- recessive (DR) model-based interaction for each 
pair of SNPs. The interactions under these four models can also be estimated by a logistic 
regression-based model similar to the AA case described above except with the 
appropriate encoding of the SNP genotypes. Alternatively, the RR, DD, DR and RD 
interactions can be estimated by explicit statistical tests (e.g. hypergeometric tests) of the 
association between a specific genotype combination of two SNPs and a disease of 
interest, where this association is compared to the association between each of the 
individual SNPs and the disease (marginal effect). Interactions estimated by logistic 
regression based models directly capture non-additive effects between two SNPs 
considering different combinations of SNP genotypes. In contrast, interactions estimated 
by explicit statistical tests have the flexibility of specifically testing certain combinations 
of genotypes for association with the phenotype. We explored alternative approaches 
both in representing different disease models and in the estimation of SNP-SNP 
interactions, and found that RR, DD, DR and RD interactions estimated by explicit 
statistical tests more likely led to the discovery of significant BPMs/WPMs in the context 
of our BridGE approach. The measure we developed based on explicit statistical tests, 
called hygeSSI, is described in detail below. The relationship between hygeSSI and 
logistic regression based models is explored in more depth in section 8.  
hygeSSI: a hypergeometric-based measurement (hygeSSI) to estimate the 
interactions 
We designed a hypergeometric-based measurement (hygeSSI) to estimate the 
interactions between two binary-coded SNPs (dominant or recessive as described above). 
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The hypergeometric p-value for a pair of binary-coded SNPs with respect to a case-
control cohort is calculated as follows: 
                                 
    
 
 
 
  
   
   
 
 
 
 
 
 
   
 
Where    and    are two SNPs; M is the total number of samples; N is the total number 
of samples in class C; K is the total number of samples that have genotype T; X is the 
total number of samples that have genotype T in class C. 
We use           and           to represent the individual SNP    and   ’s 
main effects and             ,             ,              and              to 
represent the effects of all pairs of combinations. With a nominal p-value threshold 
(      ), we first require a SNP pair to have significant association with the phenotype 
(              ). In addition, we specifically exclude instances where other allele 
combinations show significant association with the trait, i.e. we require:               
 ,                and               . 
Given a binary-coded SNP pair (     ) and a binary class label C, the following measure 
hygeSSI (Hypergeometic SNP-SNP Interaction) was defined to estimate the genetic 
interaction between two SNPs    and    (specifically for P11): 
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As described in a recent comprehensive review (24), algorithms based on 
logistic/linear regression, multifactor dimensionality reduction (MDR) (38), entropy or 
information theory (39) have been developed to measure genetic interactions. All of these 
approaches quantify the synergistic effect of SNP pairs by comparing the relative strength 
of the association between a pair of SNPs and a disease trait with the strength of the 
associations between two individual SNPs and the disease trait. A few of these 
alternatives were tested in the context of our method and did not provide the significant 
results we achieved with the metric above. We designed the above hygeSSI measure 
because it explicitly captures the interaction between combinations of specific genotypes 
of two loci. 
2.6.4 Construction of SNP-SNP interaction networks 
We constructed SNP-SNP interaction networks to serve as the basis for the 
pathway level BPM tests based on each of the disease model assumptions described 
above. An additive-additive (AA) interaction network was constructed by the described 
logistic regression based approach, where SNP-SNP edge scores were derived from the –
log10 p-value resulting from the likelihood ratio test. The recessive-recessive (RR) and 
dominant-dominant (DD) interaction networks were computed based on the hygeSSI 
metric described above, and only positive interactions were kept in the network (i.e. 
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where the joint effect of the SNP-SNP pair under the corresponding disease model was 
stronger than any marginal or alternative combination of SNPs). In addition to the above 
three networks, we also constructed a hybrid SNP-SNP interaction network in which 
interactions under recessive and dominant disease model could coexist. To do this, we 
integrated all four networks (RR, DD, RD and DR) into a single network (RD-combined) 
by taking the maximum hygeSSI among the four interaction networks for each pair of 
SNPs.  
2.6.5 Measuring pathway-pathway interactions 
Estimating pathway-pathway interactions based on the SNP-SNP interaction 
network 
For each pair of pathways, we want to test if the number of SNP-SNP interactions 
between them is significantly higher than expected given the overall density of the SNP-
SNP network as well as the marginal interaction density of the two pathways involved. 
enrichment analysis based on SNP-SNP interactions is much more computationally 
challenging, and thus we choose to binarize the hygeSSI values (based on a lenient 
threshold ) to make follow up computation efficient and scalable. After binarization, we 
divided the SNP-SNP interaction network into two networks based whether the joint 
mutation of a SNP pair is more prevalent in the case or control group, which we refer to 
as the risk and protective networks, respectively.  
For each pathway-pathway interaction, we first removed the common SNPs 
shared between two pathways. Then, we test if the observed SNP-SNP interaction density 
between two pathways is significantly higher than expected globally (the global network 
density) and locally (the marginal density of SNP-SNP interactions of the two pathways). 
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Specifically, the marginal density of a pathway is calculated as the SNP-SNP interaction 
density between the SNPs mapped to the pathway and all other SNPs in the network. We 
computed a chi-square statistic to test differences from both global and local density, 
namely chi-square global (       
   and chi-square local (      
  . The chi-square test 
assumes the SNP-SNP interactions in a network are independent, which may not be true 
for a variety of reasons. So, in addition to these chi-square statistics, we use permutation 
tests to derive an empirical p-value for each pathway-pathway interaction. To do this, we 
randomly shuffled the SNP-pathway membership (NP = 100,000-200,000 times), and for 
a given pathway-pathway interaction (    ), we compared its observed        
  and 
      
  with the values from these random permutations (        
  and        
 ) to obtain a 
permutation-based p-value.  
 
            
          
         
                
        
          
  
 
 
We used (     ) together with (       
 ) and (      
 ) for BPM discovery as 
further described in detail in the next two sections.  
Correction for multiple hypothesis testing 
Because a large number of pathway pairs (all possible pathway-pathway 
combinations) are tested in the search for significant BPMs, correction for multiple 
hypothesis testing is needed. To estimate a false discovery rate, we employed sample 
permutations (NP = 10 times) to derive the number of expected BPMS discovered by 
chance at each level of significance. We randomly shuffled the original case-control 
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groups 10 times while maintaining the matched case-control population structure. For 
each permuted dataset, the same, complete pipeline for BPM discovery was performed, 
including calculation of the SNP-SNP interaction network after permutation, which was 
then thresholded at a fixed interaction density matching the density chosen for the real 
sample labels. From these sample permutations, we obtained three null distributions 
(        
 ,        
 , and        , from which we estimated the false discovery rate (FDR) for 
each BPM (e.g.,     ). Specifically, we compared the number of BPMs observed in 
each real dataset that have better overall statistics than      with the corresponding 
random expectation estimated from the three null distributions derived from sample 
permutations (        
 ,        
 , and        : 
 
         
  
           
         
                
        
                                
          
         
               
        
                            
 
 
A simpler approach to estimate FDR would be to use only the SNP permutation-
based p-value,       , in the above formula. However, we chose to use all three 
measurements (       
 ,       
  and      ) because we observed that in some cases the 
permutation-based p-value alone did not provide enough resolution to differentiate 
among top BPMs (this could be improved with additional SNP permutations, but this is 
computationally expensive).         
  and       
  provide higher resolution measures of 
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significance of each BPM and, when combined with the permutation-based p-value, can 
differentiate among the top-most significant discoveries. 
We emphasize that we have used a hybrid permutation strategy to assess 
significance of the discovered structures. The primary permutation applied was to 
permute the SNP labels, for which 100,000-200,000 permutations were used for each 
dataset analyzed. The sample (case-control label) permutation approach mentioned above 
was used in addition to the SNP permutation strategy to estimate our false discovery rate 
across all discovered interactions. For each of the 10 sample permutations, we ran the full 
set of 100,000-200,000 SNP permutations. This hybrid approach provides a robust 
estimate of significance of the discovered pathway interactions and properly corrects for 
multiple testing. 
We also conducted a study to explore the sensitivity of our FDR estimation on the 
number of sample permutations. Specifically, for the PD-NIA dataset, we performed 
1000 sample permutations (and 200,000 SNP permutations within each of these) to 
derive an estimate of FDR for discoveries in this dataset (Table S2.25). As shown in Fig. 
S2.5, the FDRs estimated from 10 sample permutations show reasonable agreement to 
FDRs estimated from 1000 sample permutations (Pearson’s correlation of 0.81). 
Selection of disease models and density thresholds 
The method we proposed for pathway-level detection of genetic interactions is 
general in the sense that any disease model (e.g. RR, DD, RD-combined, and AA) or 
interaction statistic could be used to discover pathway-level interactions. In this study, we 
focus on prioritizing a single disease model per disease cohort for full analysis by our 
pipeline to limit the complexity of data analysis across the 13 GWAS cohorts we 
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explored with our method. Here, we describe the strategy we used to select the disease 
model to focus on for each GWAS dataset. 
To prioritize the disease model and SNP-SNP interaction network density 
threshold for each data set, we first performed a pilot experiment in which we examined 
combinations of different disease models and different density thresholds, but with fewer 
SNP permutations (Table S2.23). To exclude SNP pairs with little or weak interactions 
from our analysis, we required each SNP pair’s hygeSSI score to be at least 0.2 before 
applying density-based binarization. For each combination, we  performed 10,000 SNP-
pathway membership permutations (as compared to 100,000-200,000 for a complete run) 
to estimate FDRs using a similar procedure as that described in section 5.2, except that 
SNP permutations were used to estimate FDR instead of sample permutations, as sample 
permutations are much more computationally expensive. Based on this pilot experiment 
in each cohort, we chose the disease model and density threshold combination that 
resulted in the lowest estimated FDR for the top-most significant pathway-pathway 
interaction. The rationale of using such a pilot experiment is to identify the disease model 
that is most likely to discover significant pathway-level interactions while limiting the 
computational burden of applying our approach to several GWAS cohorts under multiple 
disease models. Based on these pilot experiments, which were performed for all 13 
cohorts, we ran the complete BridGE pipeline, including 100,000-200,000 SNP 
permutations and 10 sample permutations with the disease model and network density 
threshold chosen from the pilot experiments. The results of pilot experiments for all 
cohorts are reported in Table S2.23, and all full BPM discovery results for all diseases 
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can be found in Table S2.3 and S2.9-S2.20 as well a summary in Table S2.8. We note 
that for focused application of our approach on a single or small number of cohorts of 
interest, we would suggest exploring all possible disease models with complete runs.  
Replication in independent cohorts 
The significant BPMs discovered from one cohort could be evaluated in another 
independent cohort for replication. To determine if a discovered BPM was replicated in 
an independent cohort, we required the BPM to satisfy        
                , 
      
               , and             on the validation cohort. We also performed 
sample permutation tests (NP=10) for each validation cohort, from which we could 
generate null distributions for         
 ,       
  and       in the validation cohort. Given a 
set of discovered BPMs (e.g. FDR   0.25), we calculated fold enrichment by comparing 
the number of BPMs discovered from the original dataset that passed the validation 
criteria to the  average number of BPMs that passed the same validation criteria in the 
random sample permutations. More specifically, given a set of significant BPMs 
(          which were discovered from original cohort, the fold enrichment for 
replication is defined as: 
     
           
                 
                     
            
                  
                          
            
We also evaluated the significance of the fold enrichment by 10,000 bootstrapped BPM 
sets. Specifically, we randomly selected the same number of BPMs and used the above 
procedure to evaluate the fold enrichment, and we repeated this for 10,000 times to 
generate a null distribution for the fold enrichment scores in the validation cohort. We 
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then evaluated the significance of the fold enrichment score for our discovered BPM set 
based on this empirical null distribution. All replication results can be found in Table 
S2.6 and S2,21. 
For the BPMs that replicated in an independent cohort, we further checked if the 
SNP-SNP interactions supporting the discovered pathway-level interactions were similar 
between the cohort used for discovery and the independent cohort used for replication. 
For example, we used the BPMs discovered from PD-NIA (FDR   0.25) and for each 
BPM replicated in PD-NGRC, we computed the number of SNP-SNP interactions in 
common between the PD-NIA and PD-NGRC interaction networks as supporting 
interactions for the BPM. We used the same permutation approach as that described 
above for BPM-level validation except that the SNP-SNP interactions supporting each 
BPM were compared between the discovery and validation cohorts by a hypergeometric 
test. This was done for the real validation cohort PD-NGRC first and then repeated 10 
times under sample permutations of the validation cohort to estimate a null distribution. 
A Wilcoxon’s rank-sum test was then used to evaluate the significance of the SNP-SNP 
interaction overlap between the replicated BPMs in the real validation cohort and in the 
random sample permuted validation cohorts (Fig. 2.4B). 
BPM redundancy 
Due to the fact that many of the curated gene sets overlap, we needed to control 
for redundancy in the discovered BPMs. To do this, in reporting total discoveries, we 
filtered BPMs based on their relative overlap in terms of SNP-SNP interactions using an 
overlap coefficient. The overlap coefficient between two BPMs is defined as the number 
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of overlapping SNP pairs divided by the number of possible SNP pairs in the smaller 
BPM. 
For the significant BPMs discovered, we computed all pairwise overlap 
coefficients and used a maximum allowed similarity score of 0.25 as a cutoff. We 
reported the number of unique BPMs based on the number of connected components. For 
visualization purposes (Fig. 2.3), we selected representative BPMs from each connected 
component, prioritizing BPMs that validated in the independent cohort (PD-NGRC) for 
visualization. Significance of the validation of the set of BPMs was evaluated on the 
entire set of discovered BPMs using the permutation procedures described above, which 
directly accounts for the redundancy among the discovered BPMs. 
2.6.6 Measuring within-pathway interactions 
In addition to the between-pathway model (BPM), we also tested for enrichment 
of genetic interactions within each pathway (80) (within-pathway models, WPMs). All of 
the measures and procedures described above for BPMs apply directly to the WPM case, 
only we specifically look at SNP pairs connecting genes within the same pathways/gene 
sets instead of between pathway pairs. For WPMs, the false discovery rate and validation 
statistics were computed separately from BPMs. All WPM discovery results can be found 
in Table S2.3, S2.9-2.20. 
2.6.7 Identifying pathway hubs in the SNP-SNP interaction network  
Since both “between-pathway model” and “within-pathway model” analysis have 
been designed to avoid discoveries caused by the higher marginal interaction density of 
the individual pathways, pathways that are frequently interacting with many loci across 
the genome (as opposed to localized interactions with functionally coherent gene sets) are 
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less likely to appear in our pathway-pathway or within-pathway interactions. However, 
such pathways may also be disease relevant as they reflect pathways that modify the 
disease risk associated with a large number of other variants, so we also report pathways 
exhibiting these characteristics with BridGE (we refer to these as “PATH” discoveries in 
BridGE output files). For PATH discovery, the procedure is similar to that for BPMs and 
WPMs, with a minor modification to the scoring of each pathway. Specifically, each 
pathway is represented by a vector of pathway-associated SNPs’ degrees in the SNP-SNP 
interaction network. We then applied a one-tailed rank-sum test to compare each 
pathway-associated degree vector with the non-pathway-associated degree vector to see if 
the PATH associated SNPs exhibited significantly more interactions than the entire set of 
SNPs. PATH discovery and validation is then done by repeating the same steps as 
BPM/WPM discovery but replacing the         
  and       
  statistics with the rank-sum 
test p-value (in        scale). All PATH discovery results can also be found in Table 
S2.3 S2.9-2.20. Many of these also have clear relevance to the disease cohort in which 
they were discovered. For example, applying BridGE to discover such hub pathways in 
the context of Parkinson’s disease resulted in 3 significant pathways after removing 
redundancy (FDR ≤ 0.25), including the same Golgi-associated vesicle biogenesis gene 
set as well as the IL-12 and STAT4 signaling pathway (Biocarta) discussed in the main 
text. 
2.6.8  Comparison of hygeSSI interactions with logistic regression-based 
interactions 
We examined if the interactions captured by hygeSSI were non-additive as 
measured through a standard logistic regression-based interaction measure. We applied 
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the logistic regression model on the PD-NIA data and computed RR, DD, RD and DR 
interaction networks (binary encoding as described earlier). We also integrated these 4 
logistic regression-based networks to form an RD-combined network. Then we checked 
(1) if the top SNP-SNP interactions based on hygeSSI were significant (p≤0.05) in 
logistic regression based tests, and (2) if the significant BPMs discovered from a hygeSSI 
interaction network show significance (         
        ,         
       , and  
          ) based on SNP-SNP interactions estimated from logistic regression. This 
analysis revealed that among the top 1% hygeSSI interactions, 93% are significant based 
on a logistic regression-based test for interaction. And for the significant BPMs 
(FDR≤0.05), 100% of them are also significant if only SNP-SNP interactions also 
supported by a logistic regression model are considered. These data suggest SNP-SNP 
interactions captured by hygeSSI do represent non-additive interactions as defined based 
on a logistic regression model. Detailed results from this comparison can be found in 
Table S2.24. Further evaluation of different disease models and different measures for 
estimating SNP-SNP interactions in the context of BridGE will be the focus of future 
work. 
2.6.9 Evaluation of significance of individual SNP-SNP interaction tests 
For SNP-SNP pairs that supported the between-pathway interaction reported in Fig. 2.2B, 
we checked the statistical significance of SNP-SNP interaction pairs tested individually. 
We measured all pairwise additive-additive (AA), recessive- recessive (RR), dominant-
dominant (DD) interactions. We then performed a permutation test in which sample 
labels were permuted 10 times and for each permutation, all pairwise AA, RR, DD 
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interactions were computed for each SNP pair. These permutations were used to estimate 
a false discovery rate (FDR) for those SNP-SNP pairs supporting the reported BPM. No 
individual SNP-SNP pairs were significant after FDR-based multiple hypothesis 
correction (Fig. 2.2D, Fig. S2.1). 
2.6.10 Pathway enrichment analysis of single locus effects 
To check if the pathways involved in the significant BPMs discovered in PD-NIA 
were enriched for SNPs with moderate univariate association with Parkinson’s disease, 
we performed single pathway enrichment analysis for the same set of 685 pathways used 
for BPM discovery. In the single pathway enrichment analysis, we used a hypergeometric 
test as the SNP-level statistic for measuring univariate association (risk and protective 
associations were evaluated separately) for three different disease models: 1) recessive; 
2) dominant, and 3) a combination of recessive and dominant, in which each SNP were 
tested for both recessive and dominant disease models and the more significant one 
assigned to each SNP. We then used Wilcoxon’s rank-sum test to check if a pathway was 
enriched for SNPs with higher association than the background (all SNPs). With 10,000 
sample permutations, we computed FDR for each individual pathway (both risk and 
protective associations) by using same procedure described in 5.2. The results are 
summarized in Table S2.5. 
2.6.11 Comparison of pathways discovered by BridGE with previously 
reported disease risk loci from the GWAS catalog 
To check if previous singly-associated SNPs also appear in our discovered 
pathway-level interactions, we compared our BridGE-discovered pathways with 
pathways that could be linked to disease risk loci reported in NHGRI-EBI GWAS catalog 
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(154) (Ensembl release version 87, retrieved on Feb 6, 2017). Based on the GWAS 
catalog, the numbers of genes linked to known risk loci (p≤2.0 x 10-5) in each disease are: 
143 (144 SNPs, Parkinson’s disease), 1009 (824 SNPs, Schizophrenia), 134 (172 SNPs, 
Breast cancer), 71 (57 SNPs, Hypertension), 249 (234 SNPs, Prostate cancer) and 294 
(288 SNPs, Type II diabetes). For each disease, we summarized all pathways that were 
discovered by BridGE (FDR ≤ 0.25) and identified pathways that were implicated by 
individually associated SNPs reported in the GWAS catalog (a SNP mapping to a single 
gene in a given pathway was assumed to implicate the corresponding pathway). For 
context, for each disease, we also summarize the total number of genes implicated by 
GWAS-identified SNPs, how many these  map to the 833 pathways we used in our study, 
and how many of them can be linked to the significant pathways identified by BridGE. 
These results are presented in Table S2.22. 
2.6.12 Dependence of interaction discoveries on the assumed disease model 
While we tested multiple disease models (additive, dominant, recessive, and 
combined dominant-recessive), the most significant discoveries for the majority of 
diseases examined were reported when using a dominant or combined model as measured 
by our SNP-SNP interaction metric (86). The relative frequency of interactions under a 
dominant vs. a recessive model may be largely due to our increased power to detect 
interactions between SNPs with dominant effects compared to recessive effects. More 
specifically, individuals with both heterozygous and homozygous (minor allele) 
genotypes at two interacting loci would be affected under a dominant disease model, 
while only individuals with homozygous (minor allele) genotypes would be affected in a 
recessive disease model. The number of individuals homozygous at two interacting loci 
  64 
can be quite small depending on the allele frequency, which limits our power to discover 
them. Thus, the larger number of discoveries based on a dominant model assumption 
relative to a recessive model is likely a reflection of difference in statistical power and 
not an indication that genetic interactions among alleles with dominant effects are 
contributing more strongly to disease risk. We observed that interactions derived from an 
additive disease model provided the fewest significant discoveries when used in the 
context of BridGE based on the pilot experiments (Table S2.23). To understand this, we 
investigated whether the SNP-SNP interactions supporting the BPMs discovered under 
the combined dominant-recessive model for the PD-NIA cohort were non-additive when 
evaluated using a logistic-regression based interaction test as opposed to the direct 
association tests used for our dominant and recessive disease models (86). Most SNP-
SNP interactions supporting the PD-NIA discoveries were indeed non-additive when 
assessed using the logistic regression framework, but these were not necessarily ranked 
among the highest SNP-SNP pairs when assessed in the context of a logistic regression 
model (86) (Table S2.24), which may explain the difference in results under the additive 
vs. recessive or dominant disease models. An important distinction between the SNP-
level interaction metric we use is that we specifically identify the small subset of 
individuals with the appropriate combination of genotypes (dominant model: 
heterozygous for minor allele at two candidate loci; recessive model: homozygous for 
minor allele at two candidate loci), and directly test for association with the disease 
phenotype, whereas for the additive model, an interaction term must explain a sufficient 
fraction of the variance across the entire population for it to reach significance. This 
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distinction may play a role in why we are able to discover pathway-level genetic 
interactions with the metric proposed here but rarely with a standard additive model. It is 
worth noting that the core of the BridGE approach, discovering genetic interactions in 
aggregate rather than in isolation, is readily adaptable to other disease models or other 
statistical measures of interaction. Further exploration of different disease models as well 
as different statistical measures of interaction (149, 155) would be worthwhile. 
2.6.13 Power analysis based on interaction simulation study 
To characterize the power of our BridGE approach with respect to sample size, 
effect size, minor allele frequency and pathway size, we used a two-stage simulation 
approach. We first generated synthetic GWAS datasets with embedded SNP-SNP 
interaction pairs using GWAsimulator (134). Specially, we used PD-NIA as input to 
GWAsimulator and embedded SNP-SNP interactions with different minor allele 
frequencies (e.g. 0.05, 0.1, 0.15, 0.2 and 0.25) and a range of interaction effects (e.g. d11= 
d12=d12=d22=1.1, 1.5, 2, 2.5, 3 and 5, where 0, 1, 2 refer to the number of minor alleles 
present in a given genotype for an individual SNP, and d11, d12, d12, and d22 are defined as 
the relative risk of that genotype--11,12, 21 or 22-- versus 00) (134). We also varied the 
number of samples (genotypes) in the simulation (e.g. 200, 500, 1000, 2000, 5000 and 
10000). In all simulations, we specified the disease prevalence to be 0.05, dominance 
effect for all disease SNPs with PR1=1 (see GWAsimulator for more details) (134). 
Under different scenarios (combinations of different minor allele frequencies, interaction 
effects and sample sizes), we embedded 100 SNP pairs and measured the percentage of 
SNP-SNP interactions that were identified by our pairwise SNP-SNP interaction 
measure, hygeSSI at a 1% network density (e.g. SNP-SNP pairs whose hygeSSI is greater 
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or equal to the 99th percentile of all possible interactions) (Fig. S2.6). These simulations 
provide a direct measure of the sensitivity and specificity of the SNP-SNP interaction 
level measure that forms the basis of the pathway-level statistics. 
The SNP-SNP level power statistics were complemented with a second set of 
simulations in which we directly assessed the sensitivity of BridGE in detecting BPMs 
with different levels of noise in the SNP-SNP level network (derived from the process 
described above). To characterize the statistical power of our approach as a function of 
pathway size, we first generated a synthetic interaction network with the same degree 
distribution as the PD-NIA DD network at 1% density. Then, we embedded a set of non-
overlapping BPMs into this SNP-SNP interaction network while retaining the same 
degree distribution and density of the network. Each set had 90 BPMs at 9 different sizes 
(number of SNPs mapped to the two pathways in each BPM: 10×10, 25x25, 50×50, 
75x75, 100×100, 150×150, 200×200, 250×250 and 300×300; and 10 different 
background densities 0.01, 0.012, 0.014, 0.016, 0.018, 0.02, 0.025, 0.03, 0.04 and 0.05. 
We applied 150,000 SNP-pathway membership permutations to assess the significance of 
these embedded patterns. The SNP permutation-derived p-values of the simulations were 
reported in Fig. S2.3 and provide an estimation of BPM density required for detecting 
interactions between pathways of different sizes. We used the average p-values (p = 
3.0×10
-5
, SNP-permutation) of the significant BPM discoveries across all GWAS cohorts 
(FDR 0.25) as the discovery significance cutoff for the simulation analysis.  
We derived power estimates for each combination of parameter settings by 
integrating the results from above two simulation studies. More specifically, we 
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estimated the minimum sample size needed to discover significant BPMs at different 
pathway sizes under each of the scenarios (e.g. minor allele frequency, relative disease 
risk). To connect the two simulation studies, we require a scaling parameter (here, we 
explored s = 0.025, 0.05 and 0.1) which corresponds to the biological density of genetic 
interactions crossing each pair of truly interacting pathways. This represents the fraction 
of all possible SNP-SNP pairs crossing the pair of pathways of interest for which the 
combination of variants actually has a functional deleterious impact on the phenotype. 
This quantity is expected to be relatively small, but is difficult to estimate, which is why 
we have explored three scenarios (s = 0.025, 0.05 and 0.1). For a given BPM of a specific 
size (10×10, 25×25, 50×50, 75×75, 100×100, 150×150, 200×200, 250×250 and 
300×300), from the 2
nd
 simulation, we identified the corresponding BPM density needed 
for it to rise to the level of statistical significance required for a 25% FDR based on the 
PD-NIA cohort. We then scaled the required density by the parameter, s, and based on 
the 1
st
 set of simulation results, identified the minimum sample size required under each 
scenario (combinations of minor allele frequency, interaction effect, and sample size) to 
support the discovery of the corresponding BPM (results summarized in Fig. 2.6B).  
Simulation results for additional scaling parameters (s = 0.1 and s = 0.025) are 
included in the supplementary Fig. S2.2. These plots together provide an estimate of the 
power of the BridGE approach to detect pathway-pathway interaction in these different 
scenarios. We note that this power analysis was conducted for the dominant disease 
model, which comprises the majority of the BPM interactions discovered across all 
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cohorts. Sensitivity of our method under a recessive model assumption is expected to be 
lower, which is consistent with the relative rate of discoveries of both types.  
 
 
 
  
  69 
 
Chapter 3: Pathway-based Discovery of Genetic 
Interactions in Breast Cancer 
 
The text in this chapter is included in a manuscript that is currently in press at PLOS 
Genetics. Other contributors to this project include Zhiyuan Xu, Michael Costanzo, 
Charles Boone, Carol A. Lange and Chad Myers. More specifically, Michael helped draft 
the manuscript. Carol contributed to the interpretation of the results. Carol, Michael, 
Zhiyuan and Charles provided help interpreting the results and comments on the 
manuscript. Chad supervised the entire project. 
  
 
3.1 Introduction 
Cancer, like many common diseases, is influenced by a variety of genetic and 
environmental factors. With the rise of inexpensive genotyping technologies, the portion 
of risk due to inherited genetic variants has now been measured with unprecedented 
resolution. A recent comprehensive study reported excess familial risk for 20 of 23 
cancer types with an overall heritability estimate of 33% (156). This varied across 
different cancer types, from prostate cancer and breast cancer on the high end with 
estimated heritabilities of 57% and 31% respectively, to head and neck cancers on the 
low end with an estimated heritability of 9% (156, 157). This study concluded that at 
least for most cancers, our risk is at least partially influenced by the genes we inherit. 
As with other heritable diseases, there has been substantial interest in identifying 
specific genetic loci that increase or decrease an individual’s risk for specific cancers. 
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Over the past decade, genome-wide association studies have been the primary strategy 
for discovering such loci, and indeed, have been successful at identifying a large number 
of single-nucleotide polymorphisms (SNPs) with statistically significant association to a 
variety of diseases including cancer (66-70). However, for most diseases, there remains a 
large disparity between the disease risk explained by the discovered loci and the 
estimated total heritable disease risk based on familial aggregation (8-13). For example, 
for breast cancer, there have been approximately 100 risk loci identified to date through 
genome-wide association studies, but the combination of these loci explains only 
approximately one-third of the genetic contribution to breast cancer risk (156), a scenario 
that is typical across many diseases. There are a variety of explanations for this 
phenomenon, commonly referred to as “missing heritability”. For example, one 
explanation is that disease risk is modulated by a large number of loci, each having 
relatively small effect (8-12, 74). Alternatively, it has been proposed that rare variants, 
which are not measured by most microarray-based genotyping platforms, may be 
responsible (8-12, 74). Yet another possible explanation for our inability to explain the 
genetic component of disease is genetic interactions between combinations of common 
and/or rare loci (10, 11, 13, 22, 23).  
Genetic interactions describe combinations of two or more genetic variants whose 
combined contribution to a phenotype cannot be explained by their independent effects 
(13, 24, 75). In principle, genetic interactions can also be discovered through genome-
wide association analysis by measuring the association between specific combinations of 
variants and the disease phenotype. However, in practice, the large number of possible 
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combinations introduces both computational and fundamental statistical challenges. For a 
typical genotyping array, computing associations for all possible pairs (e.g. 10
11
 for 500k 
SNPs) is a daunting computational task. Indeed there have been efficient and scalable 
computational tools developed for this purpose (40, 47, 48, 158), but even when 
association tests can be computed, statistical power is too limited to support genome-
wide discovery of SNP-SNP interactions (13). 
We recently developed a novel method, called BridGE, for discovering genetic 
interactions from genome-wide association studies (159). The approach was designed 
based on key insights from reverse-genetic interaction screens in model organisms where 
it has been observed that genetic interactions frequently cluster into highly structured 
motifs (26, 160-162). More specifically, genetic interactions often cluster into coherent 
groups that connect or bridge across two distinct pathways. In other words, if variants in 
two different genes, each belonging to a different pathway, result in a genetic interaction, 
then any pairwise combination of deleterious SNPs in genes annotated to the two 
pathways should exhibit a similar interaction phenotype. We refer to this type of genetic 
interaction structure as a “between-pathway” model (31). The BridGE approach 
leverages this idea to explicitly search for coherent sets of SNP-SNP interactions within 
GWAS cohorts that connect groups of genes corresponding to characterized pathways or 
functional modules. Although many pairs of loci do not have statistically significant 
interactions when considered individually, they can be collectively significant if there is 
an enrichment of SNP-SNP interactions between two functionally related sets of genes 
(Fig 1A). The method imposes prior knowledge of pathway membership to exploit the 
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expected between-pathway topology of genetic networks (159). Because the number of 
hypothesis tests performed for all possible between-pathway combinations is 
substantially less than the number of tests for all possible SNP pairs (~10
5
 as compared to 
~10
11
), this enables us to extract statistically significant pathway-level interactions that 
can be associated with either increased or decreased risk of disease. 
In the current study, we describe the application of our BridGE method to breast 
cancer as part of the “Up for a Challenge-- Stimulating Innovation in Breast Cancer 
Genetic Epidemiology” (U4C) competition. Breast cancer is the second largest cause of 
cancer death among women in the U.S. with approximately 40,000 deaths annually (163). 
GWAS studies have been quite successful at identifying a number of susceptibility loci 
for breast cancer in a variety of populations (16, 164-170), but as described earlier, the 
known loci still explain only a limited portion (~one-third) of the measured heritability 
(156), suggesting that there are new genetic factors to be discovered. The U4C challenge 
presented a unique opportunity to apply our new method to several different breast cancer 
cohorts representing more than five different ethnic populations and enable a detailed 
analysis of how genetic interactions vary across different patient populations.  
We describe new pathway-level genetic interactions discovered across the U4C 
cohorts, including between-pathway as well as within-pathway interactions, which refer 
to any pairwise combination of SNPs in genes annotated to the same literature curated 
pathway and discovery of pathways that participate in many interactions (i.e. “hub-
pathways”) across 6 different populations (Table 3.1) (111, 171-174). Independent 
discoveries from each cohort are discussed along with replication analysis where the 
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proper cohorts exist. We conclude with a consensus analysis of genetic interactions, 
which revealed a set of new pathways that contribute significant genetic interactions 
across multiple cohorts. 
Table 3.1 Information about the 4 GWAS datasets used in this study 
Study Accession Platform Case Control Population Subtype Number of 
Samples used 
in BridGE  
BPC3 phs000812 Illumina 
HumanHap550v3.0; 
HumanHap 660 
1998 3263 European ER negative 3490 
CGEMS phs000147 Illumina HumanHap550 1145 1142 European Primarily ER 
positive 
2244 
MCS phs000517 Illumina  Human660W-
Quad_v1_A, Human 1M 
1878 1830 Japanese, 
Latina, 
African 
American 
Primarily ER 
positive 
1364, 282, 
390 
SBCGS phs000799 Affymetrix 6.0 2867 2285 Chinese Mixture of 
ER positive/ 
negative 
imputed 
4562, 
non-imputed 
4490 
 
3.2 Results and Discussion 
3.2.1 BridGE: a method for systematic discovery of pathway-level genetic 
interactions 
We applied our recently developed method, BridGE, to explicitly search for 
pathway-level genetic interactions from genome-wide association study (GWAS) data 
(159). The details of our method are described in our companion paper (159), but a brief 
overview is provided as part of this study (Methods). In general, BridGE takes as input 
human genotypes from matched disease/control groups, typical of that used for GWAS, 
together with a set of pathways as defined by curated functional standards (e.g. 
KEGG(34), Reactome (35), Biocarta(36)). The method then searches for instances of 
three different pathway-level models of genetic interactions, all motivated by analysis of 
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genetic interactions in yeast (26, 160-162, 175): (1) between-pathway model (BPM) (Fig. 
3.1A and C), (2) within-pathway model (WPM) (Fig. 3.1B-C), and (3) hub pathways 
(PATH) (Fig. 3.1C). Between-pathway interactions occur when two pathways impinge 
on a common function required to maintain a healthy (non-disease) state. Because the 
 
Figure 3.1Pathway-level genetic interaction models. 
(A) Between-pathway interaction and between-pathway model. Two biological pathways shared a common function 
necessary for maintaining a healthy state. Genetic variants in individual pathways do not result in a phenotype, but joint 
mutations in both pathways in the same individual results in disease. Between-pathway interactions clustering between 
two complementary pathways and appear as a bipartite graph is referred to as the between-pathway model (BPM). (B) 
Within-pathway interaction and within-pathway model. A single pathway supports a function for maintaining a healthy 
state. A single genetic variant does not result in a phenotype, but joint mutations in the same pathway results in the loss 
of function and a disease state. Within-pathway interactions clustered within the single pathway is called a within-
pathway model (WPM). (C) Overview of the framework for discovering pathway-level genetic interactions from 
GWAS breast cancer data, leveraging the BridGE method (159). 
 
two pathways can functionally compensate for each other, the disease phenotype only 
occurs when both pathways are perturbed in the same individual. Under the within-
pathway model, a single genetic variant partially disables a pathway’s function but, when 
combined with another deleterious variant affecting the same pathway, complete loss of 
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pathway function results and leads to a disease state. Pathway hubs correspond to 
pathways with frequent modifier effects where the target loci are not necessarily 
functionally coherent as under the between-pathway model, and are identified by the 
BridGE algorithm as pathways that involve SNPs with an elevated number of SNP-SNP 
interactions. Specifically, BridGE tests each pathway-level interaction structure to assess 
enrichment for SNP-SNP interactions based on three statistics (χ2global, χ2local and pperm 
for BPM and WPM) (See Methods) (159). BridGE also implements multiple disease 
models (based on the assumption that the alleles increasing susceptibility to the disease 
are recessive, dominant or additive) (159) and discovers interactions associated with both 
increased and decreased risk of the disease of interest. 
3.2.2 Analysis of genetic interactions in the BPC3 and CGEMS cohorts 
We first applied our BridGE approach to the BPC3 and CGEMS cohorts 
(phs000812 and phs00147, respectively). These cohorts are both comprised of European 
Americans with genotypes measured using a common array platform (Illumina 
HumanHap550, Table 3.1), which provides a robust basis for replication analysis. We 
note that despite a common patient ethnic group, distinct disease populations are 
represented. The BPC3 cohort is comprised exclusively of women with ER-negative 
breast cancer while the CGEMS cohort consists of women with invasive, post-
menopausal breast cancer. Previous studies suggest both unique and overlapping risk 
factors for ER negative and other breast cancers (176).  
Discovery of between pathway interactions in BPC3. Focusing first on identifying 
between-pathway model (BPM) interactions, we applied BridGE to the BPC3 cohort 
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(111). At a false discovery rate of 0.25, we identified 18 between-pathway interactions, 
corresponding to 11 distinct pathway pairs after removing redundancy (Table S3.1). All 
 
Figure 3.2 An example between pathway interaction identified from the BPC3 cohort. 
(A) Interaction between Acute Myeloid Leukemia (AML) gene set and Steroid hormone biosynthesis (SHB) gene set. 
White and yellow nodes represent the SNPs mapped to genes in the corresponding pathways and their color shows the 
significance of a univariate test in the same breast cancer cohort (white: not significant; yellow: marginally significant, 
10-4 < p < 0.05). Red lines indicate the risk associated SNP-SNP interactions between SNPs mapped to the 
corresponding pathways. (B) Null distribution of the SNP-SNP interaction density between the AML and SHB based 
on 200,000 SNP permutations. The arrow indicates the observed SNP-SNP interaction density in the BPC3 cohort. (C) 
Distribution of the significance of pairwise SNP-SNP interactions (-log10 p-value) tested individually for SNP pairs 
supporting the AML-SHB interaction. The most significant SNP-SNP interaction results in an          after 
multiple hypothesis correction, suggesting there is not sufficient power to detect SNP-SNP interactions between these 
pathways in this cohort. 
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11 interactions were associated with increased risk and were discovered under a 
combined dominant/recessive model, which integrates SNP-SNP interactions arising 
from either a recessive or dominant disease model. Across the 11 discovered BPMs, there 
were 19 total pathways involved in these pathway-pathway interactions, and many of 
them are clearly relevant to the biology of breast cancer. For example, we found evidence 
for a genetic interaction between the steroid hormone biosynthesis pathway (Reactome) 
and a gene set associated with acute myeloid leukemia (Fig. 3.2A). This gene set was 
obtained from KEGG and was created based on literature curation of the genetic events 
that are known to be crucial for leukemic transformation (many of them identified 
through somatic mutations observed for leukemias). The basis for our discovery of this 
interaction was an elevated density of SNP-SNP interactions bridging genes in these two 
pathways relative to the background density. Specifically, we observed a density of 0.05 
of weakly significant SNP-SNP pairs relative to an expected background of 0.03 in the 
entire network, which was highly significant based on a null distribution estimated from 
200,000 SNP label permutations (          ) (Fig. 3.2B). This BPM was associated 
with increased risk, which means that for each SNP-SNP interaction pair supporting the 
BPM, individuals that were either homozygous (recessive and dominant models) or 
heterozygous (dominant only) for the minor allele at two loci of interest were enriched 
among the cases (breast cancer) relative to the controls. None of the individual SNP-SNP 
interactions we identified were significant in individual pairwise tests (min. FDR = 0.94) 
(Fig. 3.2C). Furthermore, although several of the individual SNPs supporting this BPM 
exhibited moderate univariate association (               ) with breast cancer 
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incidence (21/139 in AML, 4/38 in SHB), respectively, none of them would reach a 
standard level of genome-wide significance (      ) suggesting that accounting for 
interaction between combinations of different common variants may contribute 
significantly to breast cancer heritability. 
The steroid hormone biosynthesis pathway represented a major hub among our 
discoveries for the BPC3 cohort, appearing in 8 of the 11 discovered BPMs (Fig. 3.3A). 
The steroid hormone biosynthesis pathway consists of a combination of cytochrome P450 
heme-containing proteins and hydroxysteroid dehydrogenases that are responsible for 
converting cholesterol into active steroid hormones (35). Previous studies have found an 
association between higher levels of endogenous estrogens, progesterone, cortisol, and 
androgens and higher incidence rate of breast cancer (177-179) (180). Several individual 
genetic variants that modulate steroid hormone biosynthesis levels have been explored in 
relation to breast cancer risk, perhaps most notably a variant in the CYP11A1 enzyme 
(177). Our results suggest that several common variants in this pathway may contribute to 
risk of breast cancer through genetic interactions with several other pathways. 
Replication analysis of BPC3 interactions in CGEMS cohort. We next examined if 
significant between-pathway interactions discovered in the BPC3 cohort replicated in the 
CGEMS cohort (see Methods for details). BPMs were tested for replication in the 
independent cohort using our previously described approach (159). The steroid hormone 
biosynthesis and the AML gene set (SHB-AML) BPM interaction described above was 
nominally significant (      ) by all three measures of significance. Another two 
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Figure 3.3 Summary of between-pathway and within-pathway interactions discovered from the phs000812 
(BPC3) cohort. 
(A) Network representation of a set of significant (        ) pathway-level interactions (BPM, WPM and PATH) 
that are associated with increased risk of breast cancer. Node size reflects the interaction degree. (B & C) Heatmap 
view of the interaction between the Acute Myeloid Leukemia (AML) gene set and the steroid hormone biosynthesis 
(SHB) pathway in the discovery cohort BPC3 (B) and in the replication cohort CGEMS (C). Red in the heatmap 
indicates that there is at least one SNP-SNP interaction identified between the corresponding genes. 
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BPMs, both involving interaction of the steroid hormone biosynthesis pathway with 
either Na+/Cl- dependent neurotransmitter transporters or Amine compound SLC 
transporters, were also nominally significant by 2 of the 3 measures in the CGEMS 
cohort (Table S3.2 A). In addition to evaluating the significance of the replication 
statistics for the individual BPMs, we also found that the overall degree of replication of 
the entire set of BPMs based on 10 random sample permutations was significant (Table 
S3.2 B, fold-change >15,         ). 
We further investigated whether the individual SNP-SNP interactions supporting 
the discovered pathway-level interactions between the steroid hormone biosynthesis 
pathway and the AML gene set were similar across cohorts. The set of overlapping of 
SNP-SNP interactions supporting this pathway-pathway interaction across the BPC3 and 
CGEMS cohorts was relatively small (6 SNP-SNP interactions in common, Table S3.3). 
We observed more agreement between the cohorts when considering genes implicated by 
the interactions instead of SNPs (Fig. 3.3B-C). Nonetheless, these results suggest that 
despite the common pathway-level interaction supported in both cohorts, there are 
distinct combinations of SNPs conferring disease risk between these populations, which 
is consistent with the between pathway interaction model and may explain why success 
in discovering statistically significant SNP-SNP level interactions is limited in most 
standard GWAS cohorts. 
Evidence for link between AML-associated genetic risk loci and breast cancer. 
Given the replication of the AML gene set and the steroid hormone biosynthesis pathway, 
we investigated the potential connection between AML genes and breast cancer risk. 
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Interestingly, several previous studies have explored the link between breast cancer and 
AML and show that patients surviving breast cancer tend to exhibit higher incidence of 
AML (181, 182). Although it remains unclear if this higher incidence is linked to genetic 
lesions induced by therapies used to treat breast cancer, the enrichment of SNP-SNP 
interactions connecting AML-linked genes to the hormone biosynthesis pathway 
observed in our analysis suggests that common genetic factors may contribute to 
increased susceptibility to both diseases. Interestingly, the transcription factor RUNX1 is 
included in the AML gene set and was a major driver of the BPM we discovered (Fig. 
3.3, Table S3.1). There is an established link between the Runt family of transcription 
factors (RUNX1, RUNX2, RUNX3), which have been identified as key drivers of AML 
and other cancers (183), and breast cancer. Specifically, RUNX1 is highly expressed in 
luminal and basal cells in normal breast tissue, but expression is reduced in many breast 
tumors, and lower expression of RUNX1 has been used to predict breast cancer 
metastasis (184). RUNX2 has been shown to play an oncogenic role in breast cancer 
(183, 185, 186) and its expression has been associated with the triple-negative cancers 
and correlates with poorer patient survival (185). Our data suggest that subtypes of breast 
cancer may share a common genetic basis given the fact that we observe an enrichment 
of SNP-SNP interactions connecting AML-linked genes to the hormone biosynthesis 
pathway associated with increased breast cancer risk. 
Given the right cohort with access to AML incidence post breast cancer, this 
hypothesis could be directly tested. We predict that there should be a subpopulation of 
patients whose breast cancer is due to interactions between AML-associated genes and 
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variants in the hormone biosynthesis pathway. For these patients, we would expect an 
increased incidence of AML relative to other individuals with breast cancer regardless of 
whether they were treated with chemotherapy. Such a finding could have clinical utility 
because the relevant variant combinations could be used as a diagnostic marker to avoid 
administering chemotherapy to women who harbor a subtype of breast cancer that 
predisposes them to AML. Interestingly, we did identify a recent study that provides 
indirect support for this hypothesis (187). This study focused on a set of women who 
developed leukemia after chemotherapy for breast cancer and identified germline risk 
factors enriched among these patients. The study concludes that these factors predispose 
those individuals to chemotherapy-induced leukemia. The authors also note previous 
reports of secondary AML diagnoses following only surgery or radiation treatment for 
breast cancer (188-191), supporting the idea that germline risk for AML within breast 
cancer patients even without exposure to chemotherapy may be a factor. 
Although the number of common individual SNP-SNP interaction pairs 
supporting this pathway-level interaction was relatively small between these two cohorts, 
the set that does overlap provides a starting point for more in-depth analysis. The gene- 
and corresponding SNP-pairs that supported the discovery of this BPM in both cohorts 
include: RARA-HSD11B1, RAF1-HSD11B1, LEF1-HSD11B1, ZBTB16-HSD11B1, 
FLT3-STARD4, PIK3R3-CYP19A1; corresponding SNP-SNP pairs: rs4077125-
rs742375, rs6442323-rs11119343, rs4956041-rs11119343, rs7118530-rs12143281, 
rs1933437-rs42670, rs3845301-rs3751586. Notably, a search of the NHGRI-EBI GWAS 
catalog (154) reveals that none of the genes or the SNPs involved in these pairs have been 
  83 
previously associated with breast cancer despite the clear relevance of the corresponding 
genes to cancer and evidence of genetic interactions in two independent cohorts. More 
investigation of the potential relevance of these interactions would be worthwhile. 
While the steroid hormone biosynthesis-AML pathway interaction has the 
strongest support across these two cohorts, other pathways that we found to interact with 
the steroid hormone biosynthesis pathway were also relevant to breast cancer. For 
example, one of the other risk-associated BPMs that replicated in the CGEMS cohort 
connected the steroid hormone biosynthesis pathway and an amine compound SLC 
transporter gene set (Reactome). A recent study showed that amino acid transporters (e.g. 
SLC6A14) were upregulated in tumors of epithelial origin, including breast cancer, and 
suggested this as a possible new target for cancer treatment (192). Another interaction 
connected the steroid hormone biosynthesis pathway to a Type II diabetes gene set 
(KEGG), which is interesting given previous findings that women with type II diabetes 
have elevated risk of breast cancer and suggests a potential genetic basis for this 
comorbidity (193).  
Discovery of within pathway interactions and pathway interaction hubs in BPC3 
and CGEMS. In addition to between-pathway interactions, the BridGE approach can 
also be used to identify single pathways that are enriched for SNP-SNP interactions 
mapping to multiple genes within the same pathway (within-pathway model, WPM) or 
pathways that are enriched for SNP-SNP interactions across the entire genome (pathway 
hub model, PATH). Applying BridGE to the BPC3 and CGEMS cohorts, we identified 2 
WPM and 3 PATH interactions from the BPC3 cohort and 2 WPM and 4 PATH 
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interactions on the CGEMS cohorts (Table S3.1, Table S3.4). For example, in the 
CGEMS cohort, we found that the PKA activation pathway (Reactome) was enriched for 
risk-associated WPM and PATH interactions and both types of interactions were 
replicated in a second cohort (MCS Japanese, see JPN517 in Table S3.5). PKA activation 
has been associated with prognosis and resistance to certain therapies against breast 
cancer (e.g. (194), (195)). It is worth noting that the validation of this PKA activation was 
based on a cohort consisting of Japanese women while our discovery was completed on 
women of European ancestry, which suggests this pathway may be a common breast 
cancer risk factor across different populations. 
3.2.3 Application of BridGE method to four additional breast cancer cohorts 
In addition to detailed analysis of the two European cohorts described above, we 
also applied BridGE to four additional cohorts, for a total of six cohorts: MCS (JPN, 
LTN, AA) and SBCGS (CHN) (Table 3.1). The JPN cohort was genotyped using the 
Illumina Human 1M platform, and thus, to facilitate comparison between the JPN and 
CHN cohorts, we used the imputed SNPs in the CHN cohort (Affymetrix 6.0 platform) to 
ensure enough common SNPs across two cohorts for BridGE analysis. For the CHN 
cohort, we attempted discovery both from the original genotypes as well as the imputed 
profiles. Results on the JPN cohort were originally reported in our companion paper 
(159), but are analyzed in the context of the other cohorts discussed here. BridGE was 
applied to discover between-pathway (BPM), within-pathway (WPM), and pathway hub 
(PATH) interactions independently from three out of four additional cohorts (Table 3.2, 
MCS AA cohort is omitted as it did not yield significant discoveries). 
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Table 3.2 Summary of discoveries 
Study Race Disease Model 
Interaction  
Type min(fdr) 
Number of significant discoveries (non-redundant) 
fdr 0.05 fdr 0.1 fdr 0.15 fdr 0.2 fdr 0.25 
BPC3 EUR Combined BPM 0.25 
    
18 (11) 
   
WPM 0 1 (1) 2 (1) 2 (1) 3 (2) 3 (2) 
   
PATH 0 5 (2) 8 (2) 10 (2) 10 (2) 13 (3) 
CGEMS EUR Dominant BPM 0.35 
     
   
WPM 0.23 
    
3 (2) 
   
PATH 0.13 
  
5 (4) 5 (4) 5 (4) 
MCS JPN Dominant BPM 0.15 
  
86 (37) 108 (43) 124 (48) 
   
WPM 0.4 
     
   
PATH 0.1 
 
2 (2) 2 (2) 2 (2) 2 (2) 
MCS LTN Dominant BPM 0.31 
     
   
WPM 0.92 
     
   
PATH 0.1 
 
1 (1) 1 (1) 1 (1) 1 (1) 
SBCGS CHN Combined BPM 0 12 (7) 28 (19) 38 (21) 73 (34) 84 (37) 
   
WPM 0 2 (1) 2 (1) 2 (1) 3 (1) 3 (1) 
   
PATH 0.1 
 
1 (1) 2 (1) 2 (1) 2 (1) 
 
Indeed, we were able to find genetic interactions in three of the four additional 
cohorts, although the number of interactions identified varied across cohorts as did the 
corresponding model (BPM, WPM, or PATH) (Table S3.6, Table S3.7, Table S3.8). 
Notably, the SBCGS CHN cohort, the largest of all cohorts we analyzed, produced a 
large number of discoveries (Table S3.7). For example, at an FDR of 0.25, we discovered 
37 distinct BPMs, 1 WPM, and 1 PATH interaction. Several of these involved DNA 
repair pathways. For example, the base excision repair pathway (Reactome) was involved 
in 6 of the 39 genetic interactions we discovered and included interactions with other 
pathways such as adipocytokine signaling pathway (KEGG), ubiquitin-mediated 
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proteolysis (KEGG), and a renal cell carcinoma gene set (KEGG) (Table S3.7). Some of 
the most well-known risk factors for breast cancer, e.g. BRCA1/BRCA2, PALB2, and 
ATM, are involved in DNA repair (16, 196), so the prominence of this pathway is 
perhaps not surprising. Our finding suggests that these pathways are frequent modifiers in 
this population.  
3.2.4 Consensus analysis of pathway-level genetic interactions across five 
cohorts 
The majority of the significant genetic interactions discovered across the five 
cohorts were unique to each cohort, suggesting that the strongest genetic interactions are 
distinct in each population and may reflect the broad set of ethnicities represented by 
these cohorts. However, we reasoned that there may also be common genetic interactions 
underlying breast cancer risk across diverse populations, and that if we performed joint 
discovery across these diverse cohorts, we may be able to detect such universal risk 
factors. We anticipated that pathway level interactions with moderate significance in 
individual cohorts that were consistently identified across multiple populations would be 
highly significant when analyzed together. Applying this principle, we extended our 
BridGE approach to enable joint analysis of between-, within-, and hub-pathway 
interactions across multiple cohorts. Significance of BPMs, WPMs, or PATH interactions 
with support across multiple datasets was assessed through resampling of the pathway-
level statistics from 10 sample permutations (case-control label permutations) we ran for 
all five cohorts (see Methods for details). Indeed, this analysis identified a set of BPM, 
WPM and PATH genetic interactions with significant support across multiple different 
cohorts (Fig. 3.4, Table S3.5 A, B, C, D). For example, for BPM interactions, at a 
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stringent joint significance threshold (        , see Methods for details), we 
identified 17 BPMs with support in multiple cohorts, which was significantly more than 
 
Figure 3.4 Consensus summary of pathway-level interactions discovered from the 6 GWAS breast cancer 
cohorts. 
(A) Network view of the most significant between-pathway interactions (BPM) (geometric mean           ) that 
are supported by at least two cohorts. The supporting cohorts are indicated by the edge labels. (B) List of all within-
pathway interactions (WPM) and hub pathways (PATH) that are most significant (geometric mean           ) 
and supported by at least two cohorts. 
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random expectation based on a permutation-derived null distribution (      , Table 
S3.5 D, see Methods for details). Similar analysis for WPM and PATH interactions 
suggested greater than expected coherence across the cohorts as well (Table S3.5 D).  
 
Figure 3.5 Network view of the between-pathway interactions (BPM) from the consensus analysis. 
All BPMs satisfying a geometric mean            threshold from consensus analysis are plotted. Red edges 
indicate interactions associated with increased breast cancer risk while green edges indicate interactions associated with 
decreased risk. Node size is proportional to the number of BPMs connected to each pathway. Several of the highly 
connected pathways are labeled by numbers, and their corresponding pathway names are listed. The complete 
information for these pathways can be found in S3.5 Table. 
 
We visualized the complete set of BPM interactions as a network to explore the 
relationship between the discovered interactions (Fig. 3.5). Several interesting breast 
cancer-relevant pathways emerged as part of this analysis including a vitamin D receptor 
pathway that appeared to act as a consensus interaction hub by connecting several 
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significant BPMs with support from at least two cohorts each, suggesting that the vitamin 
D receptor pathway is an important modifier of breast cancer risk. All of these 
interactions with the vitamin D receptor pathway were associated with protective effects 
(decreased risk of disease) and included interactions with integrin signaling and the toll-
like receptor signaling pathway (Fig. 3.4A). Vitamin D is a secosteroid hormone, and 
several previous studies have explored the potential protective effect of vitamin D levels 
on breast and other cancers (197, 198).  Interestingly, despite substantial interest, studies 
on the protective effects of vitamin D in cancer have produced mixed results (197). Our 
observation that the vitamin D receptor pathway participates in a large number of genetic 
interactions may suggest that only specific subsets of patients will benefit from increased 
dose of vitamin D, which is consistent with these findings.  These interactions were 
primarily supported in the MCS LTN and SBCGS CHN cohorts. Another pathway, the 
glutathione conjugation pathway (Reactome) (Fig. 3.4, Fig. 3.5), emerged as the single 
strongest consensus pathway interaction hub (PATH) associated with increased breast 
cancer risk, with support in three of the five cohorts examined (MCS LTN, MCS JPN, 
and SBCGS CHN). Several between-pathway interactions were associated with the 
glutathione conjugation pathway in the consensus analysis as well. With additional 
cohorts available, these discoveries could be assessed for replication beyond our 
consensus analysis, which would further increase confidence. 
3.2.5 Glutathione conjugation as a common breast cancer modifier 
Glutathione S-Transferases (GSTs) comprise a large and conserved family of 
enzymes that catalyze conjugation of reduced glutathione (GSH) to a variety of substrates 
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(199). GST-mediated conjugation of glutathione often leads to formation of less reactive 
products and, as a result, GSTs play an important protective role in the detoxification of 
toxins and reactive oxygen species produced as a result of oxidative stress (199). Non-
enzymatic roles have also been reported, whereby GSTs modulate specific cell functions 
through physical interaction with specific proteins and lipids in a GSH independent 
manner (199).  
Based on their broad enzymatic and non-enzymatic functions, GSTs have been 
identified as important targets for anti-inflammatory and anti-tumor drug therapies (199). 
Indeed, several GST isoenzymes have been associated with various forms of cancer. For 
example, the GSTM family of isoforms has been the focus of more than 500 studies 
examining associations between GSTM genotypes and various malignancies. One of 
these studies suggested that homozygous deletion of GSTM1 is associated with 
protective effects against breast cancer (200) while other studies proposed that GSTM1 
null alleles have a modest effect on lung cancer (201). Polymorphisms in another GST 
isoenzyme, GSTP1, have also been shown to modify response to chemotherapy in 
patients with colorectal cancer and multiple myeloma (202, 203), and GSTP1 was shown 
to influence risk of acute myeloid leukemia in patients successfully treated for breast 
cancer, non-Hodgkins lymphoma, Hodgkins and ovarian cancer (204). Furthermore, 
human tumor cell lines can overexpress GSTP1, GSTA and GSTM isoenzymes (205). In 
fact, GSTP1 overexpression is considered a major cancer biomarker that can influence 
both disease development and treatment (205). For example, GST overexpression can 
lead to enhanced GSH conjugation and inactivation of chemotherapeutic agents (199) as 
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well as aberrant regulation of cell growth and apoptosis signaling pathways caused by 
direct binding and sequestration different protein and hormone ligands (199, 205-210). 
Indeed, our systematic analysis to identify between-pathway interactions involving the 
glutathione conjugation pathway revealed a clear relationship between GSTs and cancer-
related signaling pathways (Fig. 3.6B-C, Table S3.10).  
 
Figure 3.6 Consensus interactions with the glutathione conjugation pathway. 
(A) Gene interaction degree (fold enrichment) of all glutathione conjugation genes in the three cohorts that support a 
PATH interaction for the glutathione conjugation pathway (LAT517, CHN799 and JPN517).  (B) Between pathway 
interactions associated with glutathione conjugation that are significant (        ) in both LAT517 and CHN799 
datasets. The red edges indicate they are all associated with increased risk of breast cancer. (C) Detailed statistics for 
the between pathway interactions shown in (B). 
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Given the discovery of the glutathione conjugation pathway as a pathway 
interaction hub (PATH) from our consensus analysis, we performed a full analysis of the 
three relevant cohorts to focus on discovering significant between-pathway interactions 
that specifically involved the glutathione conjugation pathway. By focusing on just this 
pathway, we further reduced the hypothesis tests to improve our power to discover 
specific pathways interacting with glutathione conjugation. This approach was successful 
for two of the three cohorts (MCS LTN, SBCGS CHN) producing 17 and 77 interactions 
at          (Table S3.10), respectively. 
Strikingly, 3 of these BPMs were independently discovered in both cohorts: 
regulation of PGC-1a, toll-like receptor 9 cascade and response to E. coli infection (Fig. 
3.6B-C). One of these pathways, PGC1A (also called PPARGC1A) regulates the activity 
of  numerous transcription factors that regulate cell growth and proliferation including 
PPARγ (Peroxisomal Proliferator-Activated Receptor γ), PPARa (Peroxisome 
proliferator-activated receptor alpha), GR (glucocorticoid receptor), THR (thyroid 
hormone receptor) and estrogen receptors (Biocarta, (211)). Not surprisingly, variants in 
PPARGC1A, PPARGC1B, PPARγ and PGC1a have been associated with familial as 
well as alcohol-related breast cancer risk (212, 213). In addition, PPARγ is upregulated in 
colon and breast cancer cells (214, 215) and relationships between PGC1a expression 
levels in breast tumors and clinical outcome have also been reported (216, 217).  
Importantly, a mechanistic link between the PGC1a pathway and the glutathione 
conjugation pathway is well established, supporting the interactions we discovered and 
suggesting increased breast cancer risk in patients carrying variants in both of these 
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pathways (199). Specifically, PPARγ is activated by binding to its ligand 15-deoxy--
prostagladin J2 (15d-PGJ2), a potent cyclopentanone (206). 15d-PGJ2 biosynthesis 
requires GST (199) and, in addition to its production, GST also regulates 15d-PGJ2 
activity by directly binding to both GSH-conjugated and unconjugated forms of 15d-PGJ2 
and sequestering the ligand in the cytosol away from its nuclear target, PPARγ (206, 
209). Indeed, stable expression of GST in a breast cancer cell line inhibited PPARγ-
dependent gene expression (206). Other studies have also shown that GST can modulate 
the activity of various signaling and metabolic pathways in a similar manner suggesting 
that sequestration by GST may represent a general mechanism for regulating pathway 
function (199, 205, 207, 208, 210). Such a regulatory role is consistent with our 
discovery of the glutathione conjugation pathway as a pathway interaction hub (PATH) 
(Fig 5A) and its interactions with a substantial number of pathways known to control cell 
growth and proliferation. 
Another interaction involving glutathione conjugation included the Toll-like 
receptor 9 (TLR9) pathway (Fig. 3.6B). TLR9 is known to control the innate immune 
response by detecting foreign DNA from microbial or other sources (218). Interestingly, 
TLR9 has been extensively studied in the context of breast cancer (219). TLR9 
expression has been measured in normal epithelial cells of the mammary gland as well as 
epithelial cancer cells and fibroblast-like tumor cells (219). TLR9 has also been shown to 
have prognostic significance specifically in triple negative breast cancers where low 
TLR9 expression is associated with shorter disease-free-specific survival. The specific 
link between TLR9 and glutathione conjugation is unclear, but the established relevance 
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of both pathways to breast cancer suggests this interaction is worth further study. In 
general, the independent discovery of several genetic interactions involving the 
glutathione conjugation pathway across multiple cohorts suggests that it likely acts as a 
common modifier for other risk factors. 
3.3 Summary and proposed future work 
We described application of our recently developed method, BridGE, to several 
breast cancer cohorts. We found significant discoveries across 5 of the breast cancer 
cohorts examined, suggesting that genetic interactions indeed play a role in determining 
breast cancer risk. Our approach leverages the key observation from reverse genetic 
screens in yeast that observed that genetic interactions often form dense clusters in which 
they bridge across two pathways, or connect pairs of genes within the same pathway. 
This observation about local structure prevalent in the yeast genetic interaction network 
provides a powerful basis for discovering interactions in human populations, and our 
results here demonstrate that this can shed new light on risk factors for breast cancer. 
We note that many of the pathways involved in genetic interactions reported here 
are novel and have never been implicated as genetic risk factors for cancer. For example, 
if we consider only BPM, WPM or PATH interactions passing a conservative cutoff of 
FDR < 0.05, we discovered a total of 25 pathways across the five cohorts (Table S3.11 
A). Based on the dbGaP GWAS catalog, traditional univariate analyses have identified 
172 distinct SNP variants associated with breast cancer (          ) from published 
GWAS. Mapping these variants to nearby genes and then to pathways reveals that only 9 
of the 25 pathways involved in the genetic interactions reported here include a gene for 
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which a SNP had previously been reported, suggesting that the remaining 16 of 25 have 
not been previously implicated through germline genetic analysis. Thus, despite their 
clear relevance to breast cancer, the majority of genetic interactions reported here 
represent novel mechanisms underlying genetic risk of breast cancer relative to previous 
studies of single variants. Interestingly, the BridGE-discovered pathways also cover 
many of the previously reported SNPs. Of the 172 unique GWAS SNPs mentioned 
above, 47 can be mapped to our collection of 833 pathways and 34 of these 47 (72%) 
map to at least one of the set of BridGE-discovered pathways (         , suggesting 
that a majority of pathways linked to previously identified SNPs from single locus 
analysis are also involved in genetic interactions.  
There were a large number of pathway-level interactions unique to individual 
cohorts we examined, suggesting that interactions can be contributed by a broad range of 
mechanisms and likely vary substantially across different human populations. We did, 
however, find evidence for a core set of interactions with support across multiple 
populations. Specifically, significant interactions involving glutathione conjugation, 
vitamin D receptor, purine metabolism, mitotic prometaphase, and steroid hormone 
biosynthesis pathways were discovered across different cohorts, suggesting these 
pathways may act as important general modifiers of breast cancer.  
There are several other interesting directions for future work based on the results 
presented here. First, one of the main inputs of the BridGE method is the definition of 
pathways, for which it then discovers genetic interactions. Of course, the quality and 
utility of the genetic interactions discovered depend on the quality of the input pathway 
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definitions. We expect that there are several pathways highly relevant to breast cancer 
that are not yet well-understood or at least not well-captured by current pathway 
databases. As these pathway definitions improve, the BridGE approach will improve in 
terms of its power in discovering interactions. In the context of breast cancer, there is a 
wealth of functional genomic data (e.g. gene expression profiles) that could directly 
inform the definition and further refinement of pathways. Leveraging these unbiased data 
to improve the input pathways before running BridGE would be worthwhile. 
Another limitation of the BridGE approach is the resolution of the discovered 
interactions. The genetic interactions reported in this study were all discovered at the 
pathway level (i.e. between or within-pathways). The premise of the method, and indeed 
the reason we are even able to discover genetic interactions, is that while power to detect 
individual pairs of SNPs with disease association is low, these associations can be 
discovered at the level of pathways. Because of this, it is typically difficult to pinpoint 
individual SNPs or combinations of SNPs for further investigation. For example, for the 
steroid hormone biosynthesis-AML gene set interaction, the BPM was discovered on the 
BPC3cohort and replicated on the CGEMS cohort. However, the overlap in the individual 
SNP-SNP interactions supporting these BPMs in the different cohorts was relatively 
small. This likely reflects both the fact that our power for detecting the actual SNP-SNP 
interactions underlying the association is limited as well as the fact that the actual SNPs 
contributing interactions between these pathways can be highly heterogeneous. Our 
analysis of the glutathione conjugation pathway discovery provides some hints at how to 
approach this challenge. Once BridGE identified the glutathione conjugation pathway as 
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a risk factor in several cohorts, we computed the density of SNP-SNP interactions 
connecting each gene in the pathway. This did highlight substantial differences in the 
SNP-SNP interaction density contributed by each gene, providing some clues as to which 
individual SNPs have the strongest contributions to the pathway-level trend (Fig. 3.6A). 
Consensus analysis of consistent SNP-level interactions across independent cohorts, 
much like we performed at the pathway level, could also be an effective strategy for 
narrowing the focus to individual variant combinations. In general, improved methods for 
further dissecting pathway-level genetic interactions to identify individual SNPs or pairs 
of SNPs responsible for a pathway-level interaction would be of interest. 
Finally, another direction worth further investigation is analysis of the clinical 
relevance of the discovered interactions. We expect that, at least in some cases, the 
genetic interactions predisposing individuals to breast cancer will influence the 
prevention, progression, and optimal treatment of the disease. Application of our method 
to large cohorts with the corresponding clinical information and development of 
predictive modeling approaches that leverage both pathway-level and SNP-level 
information from the discovered genetic interactions to model clinical features will be a 
focus of future work.  
3.4 Methods 
 
3.4.1 Datasets Used 
U4C designated Breast Cancer GWAS datasets. The National Cancer Institute 
provided seven breast cancer GWAS datasets for the U4C Stimulating Innovation in 
Breast Cancer Genetic Epidemiology Challenge:  phs000812.v1.p1, phs000147.v3.p1, 
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phs000517.v3.p1, phs000799.v1.p1, phs000851.v1.p1, phs000912.v1.p1, 
phs000383.v1.p1. Among them, we focused our analysis on four datasets: 
phs000147.v3.p1, phs000812.v1.p1, phs000517.v3.p1, and phs000799.v1.p1. A brief 
summary of these four datasets can be found in Table 3.1. 
Other datasets. We used Hapmap Phase III data (220) as our population reference data 
to filter out sample outliers. We used pathways from the MSigDB v3.0 C2 curated 
collection (50) as our candidate pathways. We required each pathway to have at least 10 
genes and at most 300 genes, and at least 10 SNPs and at most 300 SNPs after mapping 
the pathways to SNP level. A power analysis with respect to the pathway size suggested 
that our power would be limited for pathways with fewer than 10 genes (159). Thus, 
including these pathways in our testing set only exacerbates the multiple testing issues 
without a strong likelihood that we can actually discover an interaction for them. A SNP 
was mapped to all genes that overlap with a +/- 50kb window centered at the SNP, and 
then mapped to pathways to which the corresponding gene(s) were annotated.  
3.4.2 A brief overview of the BridGE method 
The details of the BridGE method are described in our separate paper (159), but 
we provide a brief overview of the approach here. Because there is not enough power to 
detect individual SNP-SNP interactions from most GWAS studies, based on the 
observation from yeast reverse genetic screen that genetic interactions often form dense 
clusters bridging across two pathways, or connect pairs of genes within the same 
pathway, we developed a method to specially search for pathway level interactions. 
More specifically, BridGE searches for three different structures: 
  99 
Between-pathway model (BPM): Between-pathway interactions occur when two 
pathways impinge on a common function required to maintain a healthy (non-disease) 
state; because the two pathways can functionally compensate for each other, the disease 
phenotype only occurs when genetic perturbations occur in both pathways in the same 
individual. 
Within-pathway model (WPM): Under the within-pathway model, a single 
genetic variant partially disables a pathway’s function and additional partial loss of 
function variants affecting the same pathway result in a complete loss of pathway 
function, leading to a disease state. 
Hub pathway model (PATH): Pathway hubs correspond to pathways with 
frequent modifier effects where the target loci are not necessarily functionally coherent as 
under the between-pathway model. 
Briefly, the BridGE approach involves the following five main components 
(159):  
(1) Data processing consisting of sample quality control, adjustment for population 
structure between the cases and controls to avoid false discoveries due to population 
stratification, and control for linkage disequilibrium (LD) by pruning the full set of 
SNPs into a unlinked subset, as LD could otherwise result in spurious BPM or WPM 
substructures. (2) Construction of SNP-SNP interaction networks based on SNP pair-
level genetic interactions scored under different disease model assumptions (additive, 
recessive, dominant or combinations of recessive and dominant models). (3) A low-
confidence, high-coverage interaction network is derived by applying a lenient 
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threshold to the SNP-SNP interaction network. (4) Pairs of pathways from predefined 
gene sets are tested for BPM or WPM enrichment of SNP-SNP pair interactions with a 
chi-squared test. The observed density is evaluated for significance based on 
comparisons to the global density (χ2global), the marginal interaction density of the two 
pathways (χ2local), as well as a permutation test (pperm) conducted by randomly shuffling 
the SNP-pathway assignment (e.g. 100K~200K times). (5) Pathway-level statistics are 
assessed for significance after correction for multiple hypothesis testing. Each pathway-
level interaction can be associated with either increased risk of disease (risk interaction: 
pairs of minor alleles linking two pathways are more frequent in the diseased 
population) or decreased risk of disease (protective interaction: pairs of minor alleles 
linking two pathways are more frequent in the control population). So, for example, for 
the between-pathway model (BPM) the number of hypothesis tests evaluated by 
BridGE is two times the number of all pair-wise pathway-pathway interactions. A 
sample permutation strategy (e.g. permutation of the case-control labels 10 times) is 
used to estimate the false discovery rate accounting for multiple hypotheses testing. 
Further details of our methods are described in (159). 
3.4.3 Data processing for the U4C datasets 
For each dataset analyzed, we followed these steps to perform quality control: (1) 
we used a standard PLINK (Purcell, et al. 2007) procedure to remove individuals with 
more than 5% missing values, and remove SNPs with more than 5% missing values, less 
than 5% minor allele frequency, or failed Hardy-Weinberg equilibrium test at 1.0E-6; (2) 
we checked relatedness among individuals, and for any pair of individuals that had a 
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proportion IBD score greater than 0.2, one of them was removed from the study; (3) we 
removed subjects that were identified as population outliers based on multidimensional 
scaling (MDS) analysis after combining the study data with HapMap phase III data (220); 
(4) we ensured balanced population structure between the cases and controls by matching 
each case with a control (implemented in PLINK with "--cluster --cc –mc 2"). All 
datasets analyzed were processed with these steps. Additional steps unique to each cohort 
are included in the sections that follow.  
phs000812 Breast and Prostate Cancer Cohort Consortium (BPC3) and phs000147 
Cancer Genetic Markers of Susceptibility Study (CGEMS). For the two breast cancer 
European cohorts, BPC3 (phs000812) and CGEMS (phs000147), since there is a partial 
overlap in cases and controls between these two cohorts, we first applied identity by 
descent (IBD) analysis to recognize these overlapping individuals and removed them 
from the BPC3 (phs000812) cohort, while keeping them in the CGEMS cohort 
(phs000147). 
phs000517 Multiethnic Cohort Study (MCS). Phs000517 dataset has three population 
groups: JPN, LTN and AA. We used MDS analysis as described above to split this cohort 
into three sub-cohorts, one for each ethnic group. Samples that did not cluster within each 
group based on MDS analysis were filtered from the cohort. These three sub-cohorts are 
also labeled as JPN517, LTN517 and AA517 respectively. 
phs000799 Shanghai Breast Cancer Genetics Study (SBCGS). To allow for direct 
comparisons with results from the phs000517 cohort, we used imputed SNPs from the 
phs000799 cohort, which was genotyped using the Affymetrix 6.0 platform, to match the 
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SNPs measured on the Human660W-Quad_v1_A and Illumina Human 1M platforms, 
which were used to genotype the phs000517 cohort. We ran our BridGE approach on 
both the non-imputed dataset and imputed dataset and reported discoveries for both. 
These imputed and non-imputed versions of the phs000799 dataset are referred to as 
“CHN799 imputed” and “CHN799 non-imputed”.  
3.4.4 Application of BridGE to discover significant BPM, WPM and PATH 
interactions in breast cancer GWAS cohorts 
We applied the BridGE method to six different cohorts derived from four GWAS 
breast cancer studies (BPC3 phs000812, CGEMS phs000147, MCS phs000517, and 
SBCGS phs000799). Specifically, we tested pathway level interactions (BPM, WPM and 
PATH) for 6 different cohorts (EUR812, EUR147, JPN517, LTN517, AA517, and 
CHN799), and for the CHN799 cohort, we used the both imputed and non-imputed data, 
independently. Details of the procedure used are described in the sections that follow. 
 For each dataset, we first ran pilot runs to find a proper set of parameters to be 
used for a full BridGE run. Specifically, we tested the four disease models (additive, 
recessive, dominant, or combinations of recessive and dominant models) with different 
network thresholds by performing a small number of SNP permutations (10,000) (SNP-
pathway assignment was randomly permuted), and estimated which combination of 
disease model and network density cutoff was the most sensitive for each dataset. 
Based on the pilot results, a recessive/dominant combined disease model was chosen 
for BPC3 (network density = 0.06), SBCGS (network density = 0.04) for both imputed 
and non-imputed version; a dominant model was chosen for CGEMS (network density 
= 0.04), MCS JPN cohort (network density = 0.04), and MCS LTN cohort (network 
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density = 0.02). For the MCS AA cohort, the pilot run suggested that we were unlikely 
to discover pathway-level interactions, so we did not apply a full BridGE run on this 
dataset in order to focus our computational resources on analysis of other cohorts. For 
all BridGE runs, we used supercomputing resources provided by the Minnesota 
Supercomputing Institute. 
As described in (159), for the discovery of between-/within-pathway 
(BPM/WPM) interactions, three metrics are used to measure the significance of the 
density of SNP-SNP interactions:  χ2global and χ2local are chi-square tests to measure 
whether the observed SNP-SNP interaction density between two pathways, or within a 
pathway, is significantly higher than expected globally (the overall network density), 
and locally (the marginal density of SNP-SNP interactions for any SNPs linked to 
genes in either of the two pathways). Additionally, a permutation test in which SNP 
labels are randomly reassigned is used to derive a third measure of significance (pperm). 
These permutations are used to establish a null distribution for χ2global and χ2local for 
each between-/within- pathway interaction. Finally, a false discovery rate is estimated 
for the entire set of between- or within-pathway interactions based on sample 
permutations in which the entire process is repeated under permutations of the case-
control labels (χ2global, χ2local and pperm) (159). 
For the hub pathway interactions (PATH), a one-tailed rank-sum test was used 
to test if the SNPs linked to each pathway show significantly more interactions than 
non-pathway SNPs, in terms of interaction degree. The sample permutation and SNP 
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label permutation procedure is same as the between- and within-pathway interaction 
discovery.  
We reported all significant BPM, WPM or PATH interactions with FDR≤0.25. 
The summary table (Table 3.2) shows that all five of the datasets have significant BPM, 
WPM or PATH level interactions. Since many of the pathways overlap with each other, 
the total number of discoveries can be inflated by the fact that many overlapping 
pathway-pathway interactions reflect the several overlapping pathways. Thus, we also 
report the number of discoveries after filtering for redundancy among the pathway 
interactions (159), and the information on overlap is included in our supplemental files. 
Detailed discovery information for each cohort can be found in (Table S3.1, Table S3.4, 
Table S3.6, Table S3.7, Table S3.8 and Table S3.9). All technical details of the BridGE 
method are described in (159). 
3.4.5 Replication analysis of discoveries in BPC3 and CGEMS 
For significant pathway level interactions identified from any of the two European 
cohorts (BPC3, CGEMS), we performed replication analysis. The disease models used 
for full interaction discovery in the BPC3 and CGEMS were different based on trends 
observed in the pilot runs (see details above), so for the replication analysis, we used the 
disease model with the discovery cohort and ran BridGE with 1000 SNP label 
permutations for all candidate pathway-level interaction. Ten sample permutations were 
also run for the replication cohort, just as in the discovery cohort. 
Significant discoveries can be validated with two different approaches. The first 
approach was to check for replication of the individual pathway-level interactions. For 
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each pathway-level interaction (e.g. BPM, WPM, or PATH), we measured all three 
significance scores ( χ2global, χ2local and pperm ) on the replication cohort and tested 
whether they met a nominal significance criteria (p ≤ 0.05). Of the discoveries from the 
BPC3 cohort, one of the 18 significant pathway-pathway interactions, the BPM 
connecting the steroid hormone biosynthesis pathway to an AML gene set was significant 
(      ) by all three measures, and two additional BPMs were significant (      ) 
by two of the three significance measures (amine compound SLC transporter gene set and 
Na(+)- and Cl(-)-dependent neurotransmitter transporters) when tested for replication in 
the CGEMS cohort (Table S3.2).  
In addition to testing for replication of individual pathway-level interactions, we 
further investigated if the total number of replicating interactions among the entire set of 
discoveries was higher than expected by chance. This “set-level” replication analysis was 
done by resampling of the same amount of pathway-level statistics from all pairwise 
pathway interactions. Further details on replication procedures are described in (159). 
3.4.6 Comparison of pathways discovered by genetic interaction analysis with 
previously reported breast cancer risk loci     
Based on the NHGRI-EBI GWAS catalog(154), there are 172 SNP variants 
(mapped to 134 genes) reported with strong association (p≤1.0 x 10-5) with breast cancer 
susceptibility. To measure the extent to which our approach produced new pathway-level 
insights about breast cancer susceptibility, we evaluated how many pathways in our 
collection were implicated basted on these 172 risk loci, and how many pathways 
discovered by BridGE analysis were novel relative to this set derived from traditional 
GWAS single variant analysis. 
  106 
Of 172 SNPs linked to known breast cancer risk loci, 47 of these SNPs could be 
mapped to our collection of 833 pathways. Then we collected all pathways that were 
identified by BridGE in any of the breast cancer cohorts analyzed here with a 
conservative FDR cutoff (        ), which yielded a total of 25 unique pathways 
either from significant BPM, WPM or PATH discoveries. Among these pathways, 9 were 
in common with the pathways already implicated by at least one known breast cancer risk 
locus. Thus our analysis of genetic interactions by BridGE has implicated 16 new 
pathways (FDR ≤ 0.05) as playing a role in breast cancer susceptibility. We listed all 
unique pathways resulted from the less stringent FDR cutoff (FDR ≤ 0.25) in Table S3.11 
A. 
3.4.7 Consensus analysis to evaluate pathway-level interactions across 
multiple cohorts  
Although we found that many pathway-level interactions discovered by BridGE 
were relevant to breast cancer, the most significant pathway-level interactions discovered 
from each cohort were relatively unique, suggesting that the strongest genetic interactions 
in each population are distinct. However, we observed that interactions discovered in one 
cohort often exhibited strong signals in additional cohorts even though they did not meet 
the stringent threshold required for discovery significance in a single cohort. Thus, we 
developed a modified version of BridGE to enable joint discovery of pathway-level 
interactions across cohorts to enable the discovery of these moderately significant, but 
consistent interactions.  
More specifically, we first ran the standard version of BridGE on 4 different 
GWAS datasets (6 total cohorts), and we summarized each pathway-level interaction 
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based on its permutation p-values (pperm) across all cohort. We then selected pathway-
level interactions that were nominally supported by at least two cohorts, for which we 
required that all test scores (χ2global, χ2local and pperm for BPMs and WPMs, degree rank-
sum test and pperm for PATH) be nominally significant (      ). For each surviving 
pathway-level interaction, we computed the geometric mean of the p-values of all 
individual cohorts that met the nominal significance requirement. These criteria 
produced a total of 3930 consensus between-pathway interactions (BPM), 76 within-
pathway interactions (WPM), and 59 hub pathway interactions (PATH), which were 
sorted based on the aggregate p-value (see Table S3.5). The most significant between-
pathway interactions (geometric mean           ), within-pathway interactions 
(geometric mean            ), and hub pathway interactions (geometric mean 
           ) are visualized in Fig. 3.4. 
 To evaluate the statistical significance of the discovered consensus interactions, 
we used the 10 random sample permutation results from each cohort. We repeated the 
same procedure described above 100 times, but each time, selecting the results from one 
of the 10 randomly permuted sample labels from each cohort, and generated consensus p-
values for these random results. We applied several cutoffs to the consensus p-values 
(geometric mean) (        ,         ,         ,         ,         , 
        , and         ) and counted how many of interactions from the real 
consensus table met the cutoff relative to the permuted results to derived an empirical p-
value for the BPM, WPM and PATH consensus observations independently. For BPMs, 
our analysis suggested the real consensus results were significantly larger than expected 
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at the chosen cutoffs (        ,         ,         ) (p < 0.02). For WPM and 
PATH, we tested geometric mean p-value cutoffs of (        ,         ,     
    , and         ). The WPM consensus interaction set was significantly larger 
than expected by a consensus p-value cutoff of 0.05 (      ). The PATH consensus 
interaction set was significantly larger than expected by chance (      ) with 
consensus p-value cutoffs of (        ,         ,             Detailed 
information for all consensus interactions is reported in (Table S3.5 A-D). 
3.4.8 Analysis of interactions for the glutathione conjugation pathway 
From the consensus interaction analysis, we identified the glutathione conjugation 
pathway as a major source of genetic interactions in multiple cohorts. As a PATH hub 
interaction, glutathione conjugation was deemed significant in MCS LTN (LTN517) and 
SBCGS (CHN799) (        ) and was also nominally significance in MCS JPN 
(JPN517). Given such strong support across different cohorts, we further investigated this 
pathway. 
Identifying genes contributing to pathway-level statistics. Given the glutathione 
conjugation pathway’s emergence as an interaction hub, we wanted to determine which 
genes in the pathway were driving these interactions. To understand this, we performed 
an interaction degree analysis on glutathione conjugation genes using the MCS LTN 
(LTN517), SBCGS (CHN799) and MCS JPN (JPN517) cohorts. We first calculated the 
interaction degree for all glutathione conjugation SNPs and then summarized them at the 
gene level. To enable comparison across cohorts, we measured a fold enrichment for each 
gene. More specifically, we first computed the interaction rate (interaction degree divided 
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by total number of SNPs in the network) and then divided it by the background 
interaction density in each dataset. This fold enrichment was averaged across all SNPs 
mapping to each gene in cases where there were more than one. This analysis showed 
that GSTM1, GSTM4, GSTP1, GSTA5’s interaction are 1.5 fold higher than background 
interactions in all three cohorts. These results are included in Fig. 3.6A. 
Identifying between-pathway interactions associated with the glutathione 
conjugation pathway. Although the glutathione conjugation pathway was enriched for 
interactions across the genome in multiple cohorts (pathway hub model), BridGE was not 
able to discover between-pathway or within-pathway interactions associated with 
glutathione conjugation when run independently on each of the three cohorts. To identify 
which pathways were interacting with glutathione conjugation gene set, we re-ran 
BridGE on two of the cohorts (MCS LTN517 and SBCGS CHN799-imputed), but only 
focused on identifying interactions with glutathione conjugation gene set, i.e. we limited 
our hypothesis tests to only BPMs that involved glutathione conjugation. This reduced 
the number of hypotheses test from more than 400k to less than 2k, substantially 
improving our power to detect interactions with glutathione conjugation. We detected 16 
pathways interacting with glutathione conjugation in MCS LTN (LTN517) and 73 in 
SBCGS (CHN799-imputed) (        ), three of which were in common. All 
glutathione conjugation related between-pathway interactions that are supported by at 
least one cohort (        ) are listed in Table S3.10. 
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Chapter 4: Identification of frequent genetic 
modifier pathways in humans based on the yeast 
genetic interaction network 
 
4.1 Introduction 
Genetic interactions occur when the joint mutations of two genes cause a 
phenotypic change that is surprising given the effects of the individual mutations. 
Genetic interactions play an important role in the structure and evolution of genetic 
systems (140). Using different model organisms, genetic interactions have been 
successfully studied and fundamental insights have been generated to reveal the 
functional relationships between gene, pathways, and biological processes (26, 221, 
222). Meanwhile, the genetic study of complex human diseases has been facing the 
challenge of finding sources of “missing heritability” for almost a decade (8-10). 
Despite the fact that the “missing heritability” problem was defined primarily based on 
models of additive genetic variation, evidence has shown that the non-additive genetic 
variations (e.g. dominance and genetic interactions) might have a significant impact on 
the measured additive genetic variance (8, 13, 223).  However, genetic interactions in 
complex human diseases have never been systematically studied due to a lack of 
statistical power. Given the rich insights into genetic interactions gained from studies of 
model organisms, there is potential we can leverage these findings to provide guidance 
for genetic interaction studies in human, and in return the validation of these discoveries 
will further advance research in model organisms. 
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Figure 4.1 Negative and positive interactions connect pathways or complexes in a coherent manner in yeast.  
This figure is reproduced from (26). (A) Network density (observed interactions/total gene pairs screened) of genetic 
interactions within and across biological processes. (B) Genetic interaction map for the proteasome 19S. (i) Regions of 
the global similarity network significantly enriched for genes exhibiting negative (red) or positive (green) genetic 
interactions with proteasome 19S members were mapped using SAFE. (ii) Protein complexes that showed coherent 
negative or positive genetic interactions with proteasome 19S were placed on a schematic representation of the global 
similarity network based on the average genetic interaction profile similarity of the complex and connected with red or 
green edges, respectively. (iii) A subset of protein complexes from (ii) that showed coherent negative (red) or positive 
(green) genetic interactions with genes encoding the proteasome are shown. 
 
Genetic interactions on a genome-wide scale in budding yeast Saccharomyces 
cerevisiae have been well studied through Synthetic Genetic Array analysis (224), an 
automated high-throughput screen technique that generates high-density yeast double 
mutant arrays. Recently, a global yeast genetic interaction network that consists of nearly 
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one million genetic interactions was released (26). Among these interactions, about 60% 
of them are negative interactions and 40% of them are positive interactions. Negative 
genetic interactions indicate double mutants that cause a more severe fitness defect than 
expected, of which synthetic lethality is one example. On the other hand, positive genetic 
interactions specify double mutants that cause a less severe fitness effect than expected, 
which could be either a scenario of genetic suppression or phenotypic masking. The 
analysis of the yeast network showed that genetic interactions are highly organized and 
negative and positive interactions connect pathways or complexes in a coherent manner 
(Fig. 4.1A) (26).  
Previously, negative genetic interactions, or synthetic lethal interactions, were 
considered more informative than positive genetic interactions because they connect 
functionally related genes (225). However, recent analysis revealed that positive 
interactions define general regulatory mechanisms (26). More specifically, the 
proteasome was found to be a densely connected positive interaction hub on the global 
yeast genetic network (Fig. 4.1B). Positive interactions between the proteasome and 
genes implicated in diverse functions, such as transcription and vesicle trafficking, were 
enriched, and a significant fraction of these interactions were confirmed to be instances of 
genetic suppression (26). Proteasome dysfunction has been associated with numerous 
human diseases (226), and proteasome inhibitors in cancer therapy have been studied for 
decades due to their anti-proliferative and pro-apoptotic activities (227-230). Since 
proteasome structure and function is highly conserved from yeast to human (231), based 
on the observation of frequent genetic suppression effects involving the proteasome in the 
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yeast study, we anticipated natural common variants in the homologous human 
proteasome genes would be associated with a number of disease-modifying genetic 
interactions. 
To test this hypothesis, we evaluated genetic interactions based on the germ-line 
mutations in complex human diseases identified through existing genome-wide 
association studies (GWAS). Specifically, we wanted to test the hypothesis that the 
proteasome tend to be strongly associated with positive interactions in human as in yeast, 
and uncover disease associated functions that interact with the proteasome. Genetic 
interactions between individual loci in large-scale genetic studies in human lack 
statistical power (13). We recently developed an approach called BridGE to take 
advantage of the interaction structures observed in yeast and overcome the statistical 
burden (159). This method leverages prior knowledge of pathway membership to exploit 
the expected pathway-level topology of genetic networks in human genome-wide 
association studies. We applied a modified version of BridGE to test proteasome’s 
protective interactions in complex human diseases. More specifically, we constructed 
genetic interaction networks across a set of nine different disease cohorts, including 
Parkinson’s disease (PD-NIA, PD-NGRC), hypertension (HT-eMERGE, HT-WTCCC), 
Schizophrenia (SZ-GAIN), type 2 diabetes (T2D-WTCCC), prostate cancer (ProC-
CGEMS), breast cancer (BC-CGEMS), and pancreatic cancer (PanC-PanScan) (Table 
4.1). We then identify genetic interaction hubs based on available annotated human 
pathway standards (34-36), which include the proteasome complex. In addition to the 
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proteasome, we also investigated genes involved in mRNA decay, which is also 
associated with diverse positive interactions in yeast (26).   
Table 3  Information about the seven genome-wide association studies (GWAS) data sets. 
N
O Disease Study dbGaP Study No. Platform Race 
Number of 
Cases/Control
s 
Number 
of SNPs 
1 
Parkinson’s 
Disease  
PD-NIA phs000089.v3.p2 
Illumina 
HumanHap550v3.0 
Europea
n 667/538 561466 
PD-
NGRC phs000196.v3.p1 
Illumina 
HumanOmni1_Quad_v1
-0_B 
Europea
n 2000/1986 
101289
5 
2 
Schizophreni
a  
SZ-
GAIN phs000021.v3.p2 Affymetrix 6.0 
Europea
n 1152/1369 845814 
3 
Breast 
Cancer  
BC-
CGEMS phs000147.v3.p1 
Illumina 
HumanHap550v1.1 
Europea
n 1145/1142 546646 
4 Hypertension 
HT-
eMERG
E phs000297.v1.p1 
Human660W-
Quad_v1_A 
Europea
n 1310/1931 561490 
HT-
WTCCC 
EGAD0000000000
6 Affymetrix 500K 
Europea
n 2001/3004 500568 
5 
Prostate 
Cancer 
ProC-
CGEMS phs000207.v1.p1 
Illumina 
HumanHap300v1.1 
Europea
n 1152/1148 317503 
6 
Pancreatic 
Cancer 
PanC-
PanScan phs000206.v5.p3 
Illumina 
HumanHap550v3.0 
Europea
n 1924/2042 558542 
7 
Type 2 
Diabetes 
T2D-
WTCCC 
EGAD0000000000
9 Affymetrix 500K 
Europea
n 1999/3004 500568 
 
4.2 Results and Discussion 
4.2.1 Modification of the BridGE method to identify interaction hubs 
BridGE is a novel computational approach that leverages the coherent structure of 
yeast genetic interactions connecting genes within and between pathways to overcome 
the statistical burden associated with identifying interactions between individual loci in 
human GWAS (159). A detailed description of the BridGE approach can be found in 
(159). Here, we modify the approach to focus on the identification of interaction hubs 
(Fig. 4.2). Details are provided in the Methods section, but the key components are 
outlined here. Genetic interactions at the SNP level (i.e. SNP-SNP pair interactions) are 
measured by hygeSSI, a measurement originally proposed in our earlier work (159). To 
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ensure sufficient statistical power to detect genetic interaction, in this study, we assumed 
a dominant disease model for all loci and SNPs at each locus were binarized as (MM=0; 
mM=Mm=1; mm=1 for m: minor allele, M: major allele). Under this setting, hygeSSI 
tests if the association between the joint occurrence of two SNPs (the “11” combination 
of two SNPs) and the disease phenotype is more significant than any individual variant 
combinations (the “10” and “01” combinations at the two loci in question) and the 
homozygous major genotype (the “00” combination at both loci). hygeSSI also estimates 
interactions associated with both increased risk and decreased risk (protective effects).  
Protective interactions reflect instances where the joint effect of two SNPs is more 
frequently observed in the control group relative to the disease group and may correspond 
to positive genetic interactions mapped in reverse genetic studies. Interactions associated 
with increased disease risk reflect cases where the joint mutations of two SNPs is more 
frequently observed in the disease group relative to the controls and may correspond to 
negative genetic interactions mapped in reverse genetic studies. 
 
Figure 4.2 Overview of the framework for identifying pathway interaction hubs from GWAS 
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 There are multiple SNPs that can be mapped to a single gene. To construct a 
gene-gene interaction network, we selected one representative SNP for each gene by 
prioritizing SNPs that are nonsynonymous and in the coding regions. Since the 
prioritization will not eliminate the many-to-one mapping problem between SNPs and 
genes, we also adopted a bootstrapping strategy to randomly pick one SNP from all 
candidates for each gene and in total we constructed 10 gene-gene interaction networks 
for each GWAS dataset.   
Pathway interaction hubs are then identified by testing if the genes involved in 
each pathway are enriched for interactions (positive or negative) across the entire set of 
SNPs, where significance is assessed through gene-pathway permutations (n=1000). 
Positive and negative interactions are evaluated separately. For each disease cohort, 
pathway hub interactions were summarized by the median empirical p-value across the 
10 bootstrapped genetic interaction networks (Table S4.1). All pathways were then 
ranked first by the total number of GWAS cohorts in which the median p-value was less 
than 0.05, then by the strength of the first quartile p-value (Table S4.2)   
4.2.2 Proteasome and mRNA decay pathways are protective interaction hubs 
in human genetic interaction networks  
As we discussed previously, the proteasome was highlighted in the recent yeast 
genetic interaction study (26). Densely connected negative and positive interactions were 
found enriched for proteasome associated bioprocesses and protein complexes. The 
topologies of negative and positive interactions in the yeast genetic interaction network 
exhibited very different characteristics. Specifically, negative interactions generally 
connect genes with coherent functions, while positive interactions tend to connect genes 
  117 
with broader, indirect regulatory relationships (26). The proteasome was found to interact 
with various functions in both the positive and negative interactions networks. In 
particular, it interacts with vesicle trafficking and transcription for positive interactions, 
and APC (anaphase-promoting complex) for negative interactions (26). Given the 
coherent interaction patterns are associated with same phenotypic change in yeast, 
proteasome associated variants in human could potentially also could interplay with other 
genetic variants, in a synthetic or suppressive manner, to modify disease risk. Although 
the specific role of the proteasome in complex human diseases is still unclear, its function 
is integral to different cellular processes. We applied the modified BridGe approach 9 
human GWAS studies and evaluate the pathway-specific interactions for ~800 pathways 
derived from the MSigDB v3.0 C2 curated collection (50).  
 
Figure 4.3 Analysis of genetic interaction hubs in human populations. 
Nine different GWAS cohorts were collected reflecting 7 different diseases. Curated human pathways were collected 
from three sources (Biocarta, Reactome, and KEGG). For each disease cohort, SNP-SNP interactions were measured 
using a novel interaction measure (18), and SNPs were mapped to corresponding gene coding regions (18). A lenient 
threshold was applied to SNP-SNP interactions (P ~ 0.05) and the frequency of interactions associated with genes in 
each pathway for each disease cohort was measured. Significance of elevated interaction density in each pathway was 
estimated through random permutations of the SNP-gene associations (18). (A) 815 pathways were ranked based on 
their median significance for protective SNP-SNP interactions under a dominant disease model across the 9 disease 
cohorts. Highly ranked pathways correspond to pathways for which the genes show a consistently elevated frequency 
of SNP-SNP interactions across several disease cohorts. The ranking of the proteasome complex (KEGG) and mRNA 
decay gene set (GO:0006402) are highlighted. (B) The pathway ranking of the proteasome based on interaction 
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frequency statistics is plotted for each of the 9 disease cohorts. Each box plot represents the distribution of rankings 
over 10 bootstrapped samplings of SNP-gene mapping as many genes have multiple SNPs mapping to them.  
 
 
Strikingly, of 800 pathways examined, the proteasome complex exhibited the 
highest median ranking across the nine disease cohorts when testing for protective effects 
(Fig. 4.3A, Table S4.2). In particular, the proteasome complex ranked among the top 2% 
of pathways with the most significantly increased density of interactions in three disease 
cohorts (prostate cancer, Parkinson’s disease, and Type 2 diabetes cohorts), and ranked 
among the top 10% - 20% of pathways in another three cohorts (Hypertension, 
Parkinson’s disease, Breast Cancer) (Fig. 4.3B, Table S4.1). The prominence of the 
proteasome in the SNP-SNP interaction network was supported by pairs of minor alleles 
whose combination resulted in decreased disease risk because they were significantly 
underrepresented in disease cohorts relative to control individuals (Fig. 4.3A-B). We also 
evaluated risk-associated proteasome interactions, and found its ranking to be low; o n 
average, it was the bottom 45% of all pathways tested. Interestingly, human orthologs of 
yeast RNA decay genes also ranked among the highest pathways (13/815) in terms of 
their frequency of SNP-SNP interactions associated with decreased disease risk (Fig. 
4.3A). The consistent high ranking of these two pathways across the nine disease cohorts 
is highly unlikely to occur by chance (P < 0.002), suggesting the possibility that, like in 
yeast (26), both the proteasome and RNA decay regulatory systems may be associated 
with numerous genetic interactions in human populations.  
 The proteasome pathway we assessed includes both the 20S proteasome core 
particle as well as the 19S proteasome regulatory particle. The proteasome, whose main 
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function is to degrade misfolded or damaged proteins into smaller peptides, is critical for 
regulating many cellular processes including the cell cycle, DNA repair, apoptosis, 
quality control and antigen presentation (232, 233). Defects in the proteasome are 
associated with different diseases and it has always been the therapeutic target, especially 
for cancer (227-229).  Currently there are four FDA approved drugs targeting the 
ubiquitin-proteasome system (UPS), which are primarily used for treating multiple 
myeloma (234, 235). For neurodegenerative diseases such as Parkinson’s disease, it has 
been speculated that the impaired function of the UPS observed in neurodegenerative 
disorders is a phenomena caused by the aggregation of disease associated proteins (236). 
However, recent evidence has suggested that the effect of disease proteins on the UPS 
system is too limited by itself to cause a loss function of the UPS (237). This implies that 
UPS dysfunction may happen before neuronal degeneration, and could instead potentially 
be a driver of the disease. Given the substantial role that the UPS system plays in cell 
development, it is now also considered as a primary target for treating neurodegenerative 
diseases (236-238).      
4.2.3 Discovering proteasome specific pathway-pathway interactions in 
human genetic interaction networks  
The purpose of the BridGE method we described previously is to identify specific 
pathway-pathway interactions (159). Specifically, the approach searches for pairs of 
pathways that are more densely connected by SNP-SNP interactions than expected. The 
enrichment of the interactions connecting two pathways is evaluated by comparing with 
two types of background interaction networks: global interaction network and the two 
local pathway interaction sub-networks, followed by a permutation test. Since our 
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objective is to detect pathway-pathway interactions involving the proteasome, we focused 
on the three GWAS cohorts in which the proteasome showed elevated levels of 
interaction (median P < 0.05 across the 10 bootstraps in each cohort), which included 
prostate cancer cohorts, Parkinson’s disease and type 2 diabetes. For each disease cohort, 
proteasome specific pathway-pathway interactions were summarized by the median 
empirical p-value across the 10 bootstrapped genetic interaction networks (Table S4.3). 
All pathways were ranked first by the total number of GWAS cohorts in which the 
median p-value was less than 0.05, and then by the strength of the median p-value across 
three cohorts (Table S4.4).   
 
 
Figure 4.4 Analysis of genetic interactions between proteasome and transcription in human populations. 
(A) A novel method, called BridGE (18), identified enrichment for protective SNP-SNP interactions between the 
proteasome and transcription-annotated pathways and complexes under a dominant disease model. (B) Enrichment for 
protective SNP-SNP interactions between the proteasome and transcription-annotated pathways was observed in the 
indicated different disease cohorts. 
 
 
 Interestingly, we detected 4 pathways or gene-sets whose interactions with the 
proteasome were supported by all three disease cohorts (prostate cancer cohorts, 
Parkinson’s disease and type 2 diabetes) (p < 0.009): biological oxidation genes, mitotic 
prometaphase, PDGF signaling and genes involved in transcription. These interactions 
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were all associated with decreased disease risk. Several of these pathways have been 
implicated in the corresponding diseases by previous studies. For example, oxidative 
stress and damage modulates carcinogenesis and its causal relationship with cancer, 
chronic degeneration in neurons, and diabetes has been heavily studied (239-244).  
Platelet-derived growth factor (PDGF) is a growth factor that regulates cell growth and 
division and links between defect of PDFG signaling and different diseases (such as 
cancer, neurodegenerative diseases, and type 2 diabetes) have been described (245-249). 
Strikingly, one of the findings resembled the relationship between the proteasome and 
transcription observed in the yeast genetic interaction network and included positive 
interactions with Transcription factor II Human (TFIIH) (26) (Fig. 4.4). Although the 
mechanistic relationship between transcription and proteasome is not clear,  recent 
studies concluded that the proteasome also performs non-proteolytic tasks that are critical 
to the regulation of transcription initiation (250-252). In general, the discovery of several 
protective genetic interactions involving the proteasome pathway across multiple cohorts 
suggests that it likely acts as a common modifier for other disease risk factors.    
4.2.4 Summary and proposed future work 
We described the development and application of  an extended version of our 
method BridGE to explore common disease modifiers of human diseases and their 
relationship to positive genetic interaction hubs observed in yeast. Positive genetic 
interactions, including genetic suppression, have the potential to inspire novel therapeutic 
approaches and elucidate mechanisms of heritability (253, 254). The yeast study showed 
that mutations compromising the proteasome often lead to suppression of defects in 
essential genes. It is possible that, similarly to yeast, certain variants of the human 
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proteasome may suppress the detrimental effects of genetic variation at other loci in the 
human genome. Indeed, we identified statistically enriched combinations of genetic 
variants involving genes encoding the human proteasome and other pathways, and these 
genetic interactions were primarily associated with protective effects in several common 
diseases (Fig.4.3-4). Interestingly, the proteasome has been considered as therapeutic 
target for many different diseases such as cancer and neurodegenerative diseases. 
These discoveries suggest that we can extract a functional wiring diagram for 
protein complexes and pathways from human GWAS data. Our results suggest that 
genetic variants in the proteasome and mRNA decay pathways commonly modify disease 
phenotypes, and highlight the potential for linking genetic interactions to human diseases. 
However, further study is required to understand the functional relevance of these 
discoveries with respect to these specific diseases. 
4.3 Materials and Methods 
4.3.1 GWAS data sources and processing 
We analyzed evidence for genetic interactions in the human population based on 9 
GWAS studies, covering 7 different diseases including breast cancer (phs000147)), 
hypertension (phs000297, EGAD00000000006)(255), pancreatic cancer (phs000206), 
Parkinson’s disease (phs000089, phs000196), prostate cancer (phs000207), schizophrenia 
(phs000021) and type 2 diabetes (EGAD00000000009). These were obtained from the 
dbGaP and Wellcome Trust Case Control Consortium (135, 255). All cohorts were 
comprised of European individuals. To enable comparison across all datasets, we 
synchronized SNP references using the Genome Reference Consortium GRCh37. All 
  123 
datasets were processed according to standard GWAS procedure using PLINK (256). 
Specifically, we required the missing genotype rate for each individual and for each SNP 
to be less than 2%, and the minor allele frequency for each SNP to be greater than 5%. 
We removed SNPs that failed a Hardy-Weinberg test at 1.0×10
6
 significance threshold. 
We also filtered genetically closely related individuals if their pairwise identity-by-
descent (IBD) estimate was greater than 0.2. In addition, we combined each dataset with 
the 1000 Genomes data (257) and performed multidimensional scaling (MDS) analysis to 
remove individuals that did not cluster with the European population. Finally, we 
controlled for population structure in each dataset by using pairwise identity-by-state 
(IBS) distance and selecting matched pairs of size 2 clusters with 1 case and 1 control 
(PLINK options “--cluster --cc --mc 2 --ppc 0.01”)(256). 
We associated SNPs to genes by considering only SNPs overlapping with coding 
regions. We gave higher priority to nonsynonymous SNPs where present, and randomly 
selected a single SNP per gene for each run. All analysis was then bootstrapped 10 times, 
randomly resampling from the available SNPs for each gene during each bootstrap. 
4.3.2 Pathways and gene sets 
Pathways and gene sets were obtained from the MSigDB curated gene set 
collection (258), which includes canonical pathways from KEGG (259), BioCarta (260) 
and Reactome (261, 262). After removing pathways with fewer than 5 genes or more than 
300 genes, there were a total of 800 pathways represented across all 9 GWAS datasets. 
4.3.3 Measuring genetic interactions between SNPs 
Our SNP-SNP interaction measure is calculated under the assumption of a disease 
model at each of the two contributing loci (either recessive or dominant). Given the 
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disease model, SNPs at each locus are binarized (e.g. dominant model: MM=0; mm, 
mM=1; recessive model: MM, mM=0; mm=1 for m:minor allele, M: major allele), which 
results in four possible states for each SNP-SNP combination under one of these disease 
models (00,01,10,11). To measure interactions, we tested for association between the 
individuals with 11 genotypes and the case/control status using a hypergeometric test, 
testing for interactions resulting in both increased risk (joint mutation more prevalent in 
case group than expected) and decreased risk or protective (joint mutation more prevalent 
in control group than expected). Pairs for which any other allele combination (00, 01, 10) 
showed nominally significant disease association were filtered out.  
4.3.4 Pathway hub analysis of gene-gene interactions 
For each bootstrapped set of SNPs in each GWAS study, we computed all 
pairwise SNP-SNP interaction scores and separately constructed the protective and risk-
associated interaction networks. To evaluate the interaction enrichment of each pathway, 
SNP-SNP interactions were binarized at a range of network densities (see below for more 
details), and a chi-squared test was used to compare the number of interactions associated 
with each pathway (e.g. interactions between proteasome genes and all other genes) with 
the total number of non-pathway associated interactions. We derived an empirical P-
value for each pathway from the resulting chi-squared statistic by using a permutation 
test, in which we shuffled the SNP labels 1000 times. The network density threshold for 
binarizing the interaction network was chosen by repeating the analysis described above 
for a range of densities. The density threshold that resulted in the largest number of 
significant pathways (median P < 0.05 across the 10 bootstraps) was selected for each 
GWAS dataset.  
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We performed this analysis for all 815 pathways, but specifically evaluated the 
ranking of the proteasome and mRNA decay pathways, motivated by our observations 
from the yeast genetic interaction network. There were two proteasome associated 
pathways in our pathway collection, one from KEGG and one from BioCarta. The KEGG 
proteasome pathway includes both 20S proteasome core particle and 19S proteasome 
regulatory particle, while the BioCarta proteasome pathway only includes 20S 
proteasome core particle. Thus, the KEGG proteasome pathway was used for our study. 
We defined the mRNA decay gene set based on human gene annotations to the mRNA 
catabolic process GO term (GO:0006402). 
We summarized pathway-level interaction statistics across all 9 GWAS cohorts 
and 10 bootstraps for each cohort. For each GWAS dataset, we first assigned each 
pathway an enrichment significance score by computing the median empirical P-value, as 
described above, across the 10 bootstraps. All pathways were then ranked first by the 
total number of GWAS cohorts in which the median P-value was less than 0.05, and then 
by the strength of the first quartile P-value. Assuming a dominant model (see description 
above), among the 800 pathways tested, the KEGG proteasome pathway ranked 1st in the 
protective interaction network and 416th in the risk-associated network. Under a 
dominant model, the mRNA decay gene set ranked 13 in the protective interaction 
network and 169 in the risk-associated network. We also repeated the analysis under a 
recessive model which resulted in corresponding ranking of 235 and 795 in the 
risk/protective networks for the proteasome and 522 and 287 in the risk/protective 
  126 
networks for the mRNA decay gene set, suggesting interactions of these pathways are 
more evident under an assumption of dominance for the minor allele. 
4.3.5 Pathway-pathway analysis of proteasome 
In addition to evaluating the overall interaction frequency of each pathway, we 
also applied our BridGE method to discover specific pathway-pathway interactions 
associated with increased/decreased disease risk (159). As our goal was to detect 
pathway-pathway interactions involving the proteasome, we focused on the three GWAS 
cohorts in which the KEGG proteasome showed elevated levels of interaction (median P 
< 0.05 across the 10 bootstraps in each cohort), which included type 2 diabetes (T2D-
WTCCC), Parkinson’s disease (PD-NIA) and prostate cancer (ProC-CGEMS) cohorts. 
Applying BridGE to these datasets, we found 4 pathways whose interactions with the 
proteasome were supported by all three: biological oxidation genes (Reactome), mitotic 
prometaphase (Reactome), PDGF signaling (Reactome) and transcription (Reactome). 
  
  127 
Chapter 5: Conclusion and Future work 
 
5.1 Conclusion 
Genetic interactions have important implications for human genetic diseases, and 
they have the potential to contribute to disease risk and explain missing heritability. Due 
to the high dimensionality of genetic data, the sample size of existing genome-wide 
association studies or next generation sequencing datasets has limited our ability to 
discover statistically significant genetic interaction through traditional association 
analysis that directly test all pairwise SNP-SNP interactions. Based on the rich insights 
derived from work in yeast, genetic interactions are less likely to occur in an isolated 
fashion between two random genes. Larger between-pathway and within-pathway 
interaction structures have been frequently observed in genetic interaction networks from 
yeast as well as other model organisms where such networks have been mapped. We 
expect these highly coherent interaction structures are likely to be conserved in all 
biological systems due to their inherent modularity, including human. This discovery 
motivated us to leverage these organizational principles to study genetic interactions in 
complex human diseases.   
We developed a novel computational approach called BridGE that enables us to 
identify pathway-based genetic interactions in different diseases. Statistically significant 
between-pathway and within-pathway interactions were discovered in the majority of 
GWAS disease datasets we evaluated. We also found evidence that suggests the 
discovered pathways are highly biologically relevant to the corresponding diseases. 
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Moreover, for any disease set in our study that has an independent cohort available, a 
significant fraction of our disease-specific discoveries could be replicated. Additionally, 
the comparison between SNPs involved in BridGE discovered pathways and the SNPs 
discovered by traditional GWAS studies further confirmed that the majority of our 
discoveries would not be made using standard univariate approaches. Novel insights 
derived from these new discoveries will help us better understand the genetic 
mechanisms responsible for human diseases, advance our capabilities to assess disease 
risk, and form the basis for new treatments. The successful application of genetic 
knowledge learned from the model organism yeast to human genetics also provides a 
compelling example of effective information exchange to bridge the gap between 
disparate research communities.    
5.2 Future work 
 Even though we have shown several promising applications of the BridGE 
method, there are still many limitations that should be noted and are worth further 
exploration. We discuss future work from two perspectives: the further improvement of 
the BridGE pipeline and the further investigation of BridGE discovered pathways for 
specific diseases. 
 The current approach depends extensively on existing pathway standards. Due to 
the complexity of biological system, our knowledge of pathway is still incomplete. Also 
the literature-curated pathways are likely biased toward cellular functions that are more 
heavily studied. While our control on the completeness of the pathways is limited, there 
is an opportunity to derive functional modules directly from disease-specific data (e.g. 
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tissue specific gene expression data) and such change could facilitate the usage of 
BridGE to capture more disease relevant interactions.  
Another limitation of BridGE is the filtering of SNPs in linkage disequilibrium 
(LD) in the data processing step. When we use this procedure to avoid detections 
spurious pathway interactions, it also caused significant loss of information. To address 
this limitation, future work could focus on choosing better representative SNPs from each 
linked region. For example, we could incorporate known functional annotations of SNPs 
or give higher priority to SNPs that are in coding region and known to be functionally 
deleterious. We could also develop methods to include all SNPs in the BridGE analysis, 
and detect and remove issues caused by LD in a post-analysis manner. Although the 
BridGE approach could also be applied to Next Generation Sequencing data, many 
components of the method need to be modified in order to focus on interactions involving 
rare variants. For example, hygeSSI will not be able to detect interactions between rare 
SNPs as currently proposed. Another clear limitation of our approach, and in fact all 
approaches that attempt to explain phenotypic variance through only analysis of genotype 
data, is that it cannot account for the effect of environmental factors and their role in 
determining disease risk. Environmental factors can be confounded with genetics or 
themselves result in heritable epigenetic changes. These effects will not be detectable 
with our approach. 
 The second perspective of future work can be very broad and much more 
challenging. Ultimately, the most important step toward demonstrating the relevance of 
discoveries made by our BridGE approach is experimental validation of the discovered 
  130 
pathways, identification of specific SNP-SNP interactions, and building of prediction 
models to assess disease risk based on discovered pathways. We do observe, when taking 
the pairs of SNPs from our discovered pathway-pathway interactions, the effect size can 
be much greater than individual SNPs discovered from traditional GWAS studies, which 
is an encouraging sign for a successful prediction model. In the future, BridGE can be 
applied to many existing GWAS studies, and we believe this could have a major impact 
on our understanding of many different diseases.  
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Supporting Information 
Supplementary Figures 
 
Figure S2.1. Distribution of p-values from individual tests for pairwise SNP-SNP 
interactions for discovered Parkinson’s disease BPM. SNP pairs supporting the 
pathway-pathway interaction between the Golgi associated vesicle biogenesis gene set 
(Reactome) and Fc epsilon receptor I signaling pathway (KEGG) discovered from the 
PD-NIA Parkinson’s disease cohort were evaluated for association with PD based on a 
recessive and dominant disease model. The distribution of maximum -log10 p-value of the 
two models for each SNP pair is plotted. None of the SNP pairs are significant after 
multiple hypothesis correction (dashed line at the most significant SNP-SNP pair 
corresponds to FDR=0.95). 
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Figure S2.2 Power analysis of the effect of minor allele frequency (MAF), BPM size, 
interaction effect size, and sample size on the discovery of between-pathway 
interactions. The plot is same as Fig. 2.6B, but the biological densities used are 2.5% (A) 
and 10% (B). 
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Figure S2.3 Power simulation of the effect of pathway size and interaction density 
on the discovery of between-pathway interactions. The BPM significance (       p-
value derived from 150,000 SNP permutations) is plotted for 100 embedded BPMs of 
different sizes and SNP-SNP interaction densities (online method). The gray plane 
indicates the p-value cutoff corresponding to the average SNP permutation p-values (p = 
3.0×10
-5
) of the significant BPM discoveries across all GWAS cohorts (FDR 0.25). Bars 
exceeding this plane represent BPMs that would have been discovered in this cohort and 
provide an estimate of sensitivity of the approach.  
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Figure S2.4 Distribution of sizes for discovered BPMs. The size of each candidate 
BPM was measured as the total number of possible SNP-SNP pairs between the two 
pathways. The distribution of sizes of all possible pathway-pathway pairs is plotted in (A) 
and only significant BPMs (FDR ≤ 0.25) from the PD-NIA cohort are plotted in (B). 
BPMs discovered by BridGE span a large range of sizes.  
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Figure S2.5 Comparison of false discovery rates derived from 10 sample 
permutations vs. 1000 sample permutations using PD-NIA dataset. BPMs that are 
significant (FDR 0.25) based on either 10 sample permutations or 1000 permutations 
were plotted to show the agreement between two permutations.  
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Figure S2.6 Power simulation of the effect of sample size, interaction effect size and 
minor allele frequency on the discovery of SNP-SNP interactions0, The discovery 
rates of 100 embedded SNP-SNP interactions in the synthetic datasets with different 
sample sizes were plotted and colored with corresponding interaction effect size. Each 
subplot is corresponded to a different minor allele frequency assumption: (A) MAF=0.05, 
(B) MAF=0.1, (C) MAF=0.15, (D) MAF=0.2, (E) MAF=0.25. 
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Supplementary Tables  
Table S2.1 Information about the 13 genome-wide association studies (GWAS) data 
sets used in this study. 
 
Table S2.2 List of 833 gene sets from KEGG, BioCarta and Reactome. 
 
Table S2.3 BridGE results from PD-NIA cohort based on recessive/dominant 
combined disease model. BridGE results are reported for the PD-NIA cohort, with the 
following tabs (in order):  summary of discoveries, between-pathway model (BPM) 
interactions, within-pathway model (WPM) interactions, and hub pathways (pathways 
exhibiting elevated density of SNP-SNP interactions across the genome) (PATH). 
Decreased risk (protective) and increased risk (risk) interactions are listed separately. 
These results were derived using the combined recessive-dominant disease model. 
 
Table S2.4 List of BPMs and WPMs after filtering for redundancy for the PD-NIA 
cohort. This file contains a list of BPMs obtained from the PD-NIA cohort after 
controlling for redundancy based on a maximum overlap coefficient of 0.25. These 
correspond to the set visualized in Fig. 2.3A of the manuscript. 
 
Table S2.5 Pathway enrichment analysis for single locus effects for PD-NIA. 
Pathway enrichment analysis on single locus effects was computed for several different 
disease models and subsets of SNPs. Each of the following tabs appears in this file: (A) 
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combined disease model, LD controlled SNP set, (B) dominant disease model, LD 
controlled SNP set, (C) recessive disease model, LD controlled SNP set, (D) combined 
disease model, genome-wide SNP set, (E) dominant disease model, genome-wide SNP 
set, (F) recessive disease model, genome-wide SNP set. 
 
Table S2.6 Replication statistics and lists of replicated BPMs for BridGE discoveries 
from PD-NIA. BPMs discovered from the PD-NIA cohort were tested for replication in 
the independent PD-NGRC cohort. Tab (A) contains a summary of replication statistics 
and tab (B) contains a list of replicated BPMs. 
 
Table S2.7 Summary of between and within-pathway interactions discovered across 
six diseases. This file contains a list of BPMs and WPMs (top 10) discovered across six 
diseases. These correspond to the set visualized in Fig. 2.5 of the manuscript. 
 
Table S2.8 Summary of interactions discovered across 13 GWAS cohorts. The 
number of between-pathway model (BPM) interactions, within-pathway model (WPM) 
interactions, and hub pathways (pathways exhibiting elevated density of SNP-SNP 
interactions across the genome) (PATH) discovered are reported for each of the 13 
GWAS cohorts at a range of FDR cutoffs. 
 
Table S2.9 BridGE results from PD-NGRC cohort based on dominant disease 
model. BridGE results are reported for the PD-NGRC cohort, with the following tabs (in 
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order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant disease model. 
 
Table S2.10 BridGE results from SZ-GAIN cohort based on combined disease 
model. BridGE results are reported for the SZ-GAIN cohort, with the following tabs (in 
order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately.These results were derived 
using the combined recessive-dominant disease model. 
 
Table S2.11 BridGE results from SZ-CATIE cohort based on recessive disease 
model. BridGE results are reported for the SZ-CATIE cohort, with the following tabs (in 
order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately.These results were derived 
using the recessive disease model. 
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Table S2.12 BridGE results from BC-CGEMS-EUR cohort based on recessive 
disease model. BridGE results are reported for the BC-CGEMS-EUR cohort, with the 
following tabs (in order):  summary of discoveries, between-pathway model (BPM) 
interactions, within-pathway model (WPM) interactions, and hub pathways (pathways 
exhibiting elevated density of SNP-SNP interactions across the genome) (PATH). 
Decreased risk (protective) and increased risk (risk) interactions are listed separately. 
These results were derived using the recessive model. 
 
Table S2.13 BridGE results from BC-MCS-JPN cohort based on dominant disease 
model. BridGE results are reported for the BC-MCS-JPN cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
 
Table S2.14 BridGE results from BC-MCS-LTN cohort based on dominant disease 
model. BridGE results are reported for the BC-MCS-LTN cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
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and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
 
Table S2.15 BridGE results from HT-eMERGE cohort based on dominant disease 
model. BridGE results are reported for the HT-eMERGE cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
 
Table S2.16 BridGE results from HT-WTCCC cohort based on combined disease 
model. BridGE results are reported for the HT-WTCCC cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the recessive-dominant combined model. 
 
Table S2.17 BridGE results from ProC-CGEMS cohort based on dominant disease 
model. BridGE results are reported for the ProC-CGEMS cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
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pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
 
Table S2.18 BridGE results from ProC-BPC3 cohort based on dominant disease 
model. BridGE results are reported for the ProC-BPC3 cohort, with the following tabs (in 
order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
 
Table S2.19 BridGE results from PanC-PanScan cohort based on dominant disease 
model. BridGE results are reported for the PanC-PanScan cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the dominant model. 
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Table S2.20 BridGE results from T2D-WTCCC cohort based on combined disease 
model. BridGE results are reported for the T2D-WTCCC cohort, with the following tabs 
(in order):  summary of discoveries, between-pathway model (BPM) interactions, within-
pathway model (WPM) interactions, and hub pathways (pathways exhibiting elevated 
density of SNP-SNP interactions across the genome) (PATH). Decreased risk (protective) 
and increased risk (risk) interactions are listed separately. These results were derived 
using the recessive-dominant combined model. 
 
Table S2.21 Replication statistics and lists of replicated BPMs, WPMs or PATHs for 
BridGE discoveries from prostate cancer, breast cancer and schizophrenia. BPMs, 
WPMs and PATHs discovered from the each disease cohort were tested for replication in 
the corresponding independent cohort, for each of the three diseases. Both a summary of 
replication statistics and a list of replicated BPMs, WPMs or PATHs are reported, with 
one disease cohort per tab. 
 
Table S2.22 Comparison between BridGE pathways and SNPs reported in the 
GWAS catalog.  Summary of the comparison (A) and list of pathways identified by 
BridGE with FDR 0.25 and their association with GWAS SNPs for the six diseases 
studied: (B) Parkinson’s disease, (C) Schizophrenia, (D) Breast cancer, (E) Hypertension, 
(F) Prostate cancer and (G) Type II diabetes. 
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Table S2.23 Results of pilot experiments for 13 GWAS cohorts. As described in 
methods, all 13 cohorts on which BridGE was applied were first explored in pilot runs in 
which a smaller number of SNP permutations. Based on initial estimates of FDR, the 
disease model and density combination with strongest statistical significance were run in 
full. Pilot results from all 13 cohorts are included in this file, one per tab. 
 
Table S2.24 Summary of evaluation of hygeSSI SNP-SNP interactions by a logistic 
regression-based interaction test. 
 
Table S2.25 BridGE results from PD-NIA cohort based on recessive/dominant 
combined disease model using 1000 sample permutations. BridGE results are reported 
for the PD-NIA cohort, with the following tabs (in order):  summary of discoveries, 
between-pathway model (BPM) interactions, within-pathway model (WPM) interactions, 
and hub pathways (pathways exhibiting elevated density of SNP-SNP interactions across 
the genome) (PATH). Decreased risk (protective) and increased risk (risk) interactions 
are listed separately. These results were derived using the combined recessive-dominant 
disease model. 
 
Table S3.1 BridGE results from BPC3 cohort based on recessive/dominant 
combined disease model. (A) List of between-pathway interactions discovered in this 
cohort; (B) List of within-pathway interactions discovered in this cohort; (C) List of 
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pathway hub interactions discovered in this cohort; (D) Corresponding pathway names 
for Fig. 2.3A. 
Table S3.2 Replication analysis using BPC3 as discovery cohort and CGEMS as 
confirmation cohort. (A) List of replicated between-pathway interactions (BPMs); (B) 
Replication statistics. 
Table S3.3 Detailed information about interaction between steroid hormone 
biosynthesis (SHB) and acute myeloid leukemia (AML) 
Table S3.4 BridGE results from CGEMS cohort based on dominant disease model. 
(A) List of within-pathway interactions discovered in this cohort; (B) List of pathway hub 
interactions discovered in this cohort. 
Table S3.5 Consensus summary of BridGE results across 5 different cohorts. (A) 
List of between-pathway interactions from the consensus analysis; (B) List of within-
pathway interactions from the consensus analysis; (C) List of pathway hub interactions 
from the consensus analysis; (D) Statistical significance results for consensus analysis; 
(E) Corresponding pathway names for Fig. 3.4. 
Table S3.6 BridGE results from MCS LTN cohort based on dominant disease 
model. (A) List of pathway hub interactions discovered in this cohort. 
Table S3.7 BridGE results from SBCGS CHN cohort based on recessive/dominant 
combined disease model. (A) List of between-pathway interactions discovered in this 
cohort; (B) List of within-pathway interactions discovered in this cohort; (C) List of 
pathway hub interactions discovered in this cohort. 
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Table S3.8 BridGE results from MCS JPN cohort based on dominant combined 
disease model. (A) List of between-pathway interactions discovered in this cohort; (B) 
List of within-pathway interactions discovered in this cohort; (C) List of pathway hub 
interactions discovered in this cohort. 
Table S3.9 BridGE results from SBCGS CHN (imputed) cohort based on 
recessive/dominant combined disease model. (A) List of pathway hub interactions 
discovered in this cohort. 
Table S3.10 Between-pathway interactions involved with glutathione conjugation 
from SBCGS CHN and MCS LTN cohorts. 
Table S3.11 Comparison between BridGE pathways with GWAS breast cancer 
SNPs.  List of pathways identified by BridGE across 5 different cohorts with FDR<0.25 
and their link to GWAS genes. 
Table S4.1 Pathway hub analysis results from each individual GWAS dataset. 
Permutation based enrichment score for each pathway was listed for 10 bootstraps.  
Table S4.2 Pathway hub analysis summary. Pathway hub enrichment scores were first 
summarized by the median empirical p-value across 10 bootstraps for each GWAS 
dataset. Then pathways were ranked first by the total number of GWAS cohorts in which 
the median p-value was less than 0.05, and then by the strength of the first quartile p-
value. 
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Table S4.3 Proteasome associated pathway-pathway interaction analysis results 
from each individual GWAS dataset. Permutation based enrichment score for each 
pathway-pathway interaction was listed for 10 bootstraps. 
Table S4.4 Proteasome associated pathway-pathway interaction analysis summary 
(T2D-WTCCC , PD-NIA, and ProC-CGEMS). Proteasome associated pathway-
pathway interaction enrichment scores were first summarized by the median empirical p-
value across 10 bootstraps for each GWAS dataset. Then pathways were ranked first by 
the total number of GWAS cohorts in which the median p-value was less than 0.05, and 
then by the strength of the first quartile p-value. 
 
